WO2010141507A1 - Biomolecule-polymer conjugates and methods of making same - Google Patents
Biomolecule-polymer conjugates and methods of making same Download PDFInfo
- Publication number
- WO2010141507A1 WO2010141507A1 PCT/US2010/036957 US2010036957W WO2010141507A1 WO 2010141507 A1 WO2010141507 A1 WO 2010141507A1 US 2010036957 W US2010036957 W US 2010036957W WO 2010141507 A1 WO2010141507 A1 WO 2010141507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomolecule
- polymer
- conjugate
- formula
- poly
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 187
- 238000000034 method Methods 0.000 title claims abstract description 59
- -1 poly(lactide) Polymers 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 50
- 239000002202 Polyethylene glycol Substances 0.000 claims description 44
- 229920001223 polyethylene glycol Polymers 0.000 claims description 44
- 150000001345 alkine derivatives Chemical class 0.000 claims description 40
- 108020004459 Small interfering RNA Proteins 0.000 claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 229920000249 biocompatible polymer Polymers 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 10
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 9
- 239000010949 copper Substances 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000002679 microRNA Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108091070501 miRNA Proteins 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 229930182556 Polyacetal Natural products 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 5
- 229920002732 Polyanhydride Polymers 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 5
- 229920001710 Polyorthoester Polymers 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 5
- 229920002313 fluoropolymer Polymers 0.000 claims description 5
- 239000004811 fluoropolymer Substances 0.000 claims description 5
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
- 229940065514 poly(lactide) Drugs 0.000 claims description 5
- 239000002745 poly(ortho ester) Substances 0.000 claims description 5
- 229920002492 poly(sulfone) Polymers 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229920002647 polyamide Polymers 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000004632 polycaprolactone Substances 0.000 claims description 5
- 239000004417 polycarbonate Substances 0.000 claims description 5
- 229920000515 polycarbonate Polymers 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 5
- 229920000570 polyether Polymers 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920006324 polyoxymethylene Polymers 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- 239000004800 polyvinyl chloride Substances 0.000 claims description 5
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 5
- 229920002620 polyvinyl fluoride Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 description 69
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 108091034117 Oligonucleotide Proteins 0.000 description 31
- 229920002477 rna polymer Polymers 0.000 description 29
- 239000004055 small Interfering RNA Substances 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000006731 degradation reaction Methods 0.000 description 23
- 230000015556 catabolic process Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 125000004429 atom Chemical group 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- RAMTXCRMKBFPRG-UHFFFAOYSA-N prop-2-ynyl carbonochloridate Chemical compound ClC(=O)OCC#C RAMTXCRMKBFPRG-UHFFFAOYSA-N 0.000 description 18
- ZUHZGEOKBKGPSW-UHFFFAOYSA-N tetraglyme Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 16
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- 230000029087 digestion Effects 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 101710113436 GTPase KRas Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 125000000524 functional group Chemical group 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 125000002355 alkine group Chemical group 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 229940014144 folate Drugs 0.000 description 7
- 235000019152 folic acid Nutrition 0.000 description 7
- 239000011724 folic acid Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 229920001519 homopolymer Polymers 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 6
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 6
- 235000012141 vanillin Nutrition 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 5
- 238000012650 click reaction Methods 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 150000003852 triazoles Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006352 cycloaddition reaction Methods 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 230000007515 enzymatic degradation Effects 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 0 *NC(CCC#I)=O Chemical compound *NC(CCC#I)=O 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920005604 random copolymer Polymers 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 2
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 229910004749 OS(O)2 Inorganic materials 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 150000001734 carboxylic acid salts Chemical class 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KQLXBKWUVBMXEM-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 KQLXBKWUVBMXEM-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 101710201076 Carboxylesterase 1 Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150093156 Rras gene Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241001496998 Streptomonospora Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000010462 azide-alkyne Huisgen cycloaddition reaction Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical group Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 108010076770 hemoglobin polymer Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Definitions
- biomolecules for examples small biomolecules (lipids, phospholipids, glycolipids, sterols, vitamin, hormones, neurotransmitters, carbohydrates, sugars, disaccharides, natural products), bimolecular monomers (amino acids, nucleotides, monosaccharides), and bimolecular polymers (peptides, oligopeptides, polypeptides, proteins, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), oligosaccharides, polysaccharides, and lignin).
- small biomolecules lipids, phospholipids, glycolipids, sterols, vitamin, hormones, neurotransmitters, carbohydrates, sugars, disaccharides, natural products
- bimolecular monomers amino acids, nucleotides, monosaccharides
- bimolecular polymers peptides, oligopeptides, polypeptides, proteins, ribonucleic acids (RNA), deoxyribonucleic acids
- RNA small interfering RNA
- mRNA micro RNA
- Small interfering RNA refers to RNA oligonucleotides that modulate protein expression.
- Small interfering RNAs offer great potential in the treatment of numerous diseases, such as cancer, but have failed to reach their full potential due to an inability to reach the site of action in an active form. See R. James Christie et al Endocrinology, 2010, 151(2), 466-473.
- RNA interference generally refers to a pathway in eukaryotic cells for sequence-specific targeting and cleavage of complementary messenger RNA. See S. M. Elbashir et al., Nature, 2001, 411, 494-498. This is accomplished through the delivery of complementary strands of DNA or RNA into cells, complexation of these strands with proteins or enzymes that allow for the degradation or inhibition of mRNA thereby inhibiting cellular mechanisms.
- siRNA delivery in clinical trials involves local delivery of an siRNA to the site of action to treat maladies such as age-related macular degeneration (AMD).
- AMD age-related macular degeneration
- This technique does not utilize a protective mechanism to prevent the degradation of the siRNA or provide a selective targeting mechanism to increase the specificity of the siRNA delivery, and as such does not address the above-described problems. Indeed, this delivery technology is limited to local administration of therapeutically high doses of the siRNA.
- biomolecule-polymer conjugate(s) of Formula 1 is provided herein.
- the linker L is independently a 1 - 20 atom linear or branched linker; the polymer is independently a biocompatible polymer; X is independently an atom of attachment to the biomolecule that is O, NH, NR, or S, where R is part of the biomolecule; n is an integer from about 1 to about 30; and the X — L bond is degradable.
- the L — triazole bond can be to either carbon of the triazole ring, and is represented by the loose bond as illustrated in Formula 1.
- the biomolecule of Formula 1 is a nucleotide, nucleic acid, polynucleotide, amino acid, peptide, polypeptide, protein, or polysaccharide.
- a method of preparing a biomolecule-polymer conjugate(s) of Formula 1 comprises: (a) reacting the biomolecule with an alkyne-containing electrophilic reagent, and (b) reacting the alkyne- modified biomolecule with an azide-containing polymer or mixture of azide-containing polymers.
- the reaction is illustrated in Scheme 1 below:
- kits suitable for preparing a biomolecule-polymer conjugate(s) of the disclosure comprising an alkyne-containing electrophilic reagent in a first container, an azide-containing biocompatible polymer in a second container, and instructions for their use.
- the invention is based, in part, on the surprising and unexpected discovery of biomolecule-polymer conjugates that have increased stability compared to unmodified biomolecules, yet retain their efficacy against their intended target.
- FIG. IA illustrates an embodiment of the first step of the method described herein, wherein an adenine amino group is reacted with propargyl chloroformate.
- FIG. IB illustrates an embodiment of the first step of the method described herein, illustrating modification of one or more amino and hydroxyl groups of various nucleobases.
- FIG. 2 illustrates an embodiment of the second step of the method described herein, where an alkyne-containing biomolecule, the product of the first step of the method, is reacted with an azide-containing polymer, to form a biomolecule-polymer conjugate(s) of the disclosure.
- FIG. 3A illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an siRNA is conjugated to multiple azide-containing polymers;.
- FIG. 3B illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an alkyne-modified biomolecule is conjugated to multiple azide-containing polymers.
- FIG. 3C illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an siRNA is conjugated to multiple azide-containing polymers terminated with a functional group.
- FIG. 4 illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure that is a biomolecule-polymer conjugate network.
- FIG. 5 shows Thin Layer Chromatography ("TLC") results under ultraviolet (“UV") light showing deoxyribonuclease (“DNase”) I digestion after one hour of an oligonucleotide-MPEG conjugate prepared from methoxy-polyethylene glycol with an average molecular weight of 550 (“MPEG550”), the unmodified oligonucleotide, and a blend of the unmodified oligonucleotide and MPEG550.
- TLC Thin Layer Chromatography
- UV ultraviolet
- DNase deoxyribonuclease
- FIG. 6 shows TLC results under UV light showing DNase I digestion after six hours of the conjugate and unmodified oligonucleotide of FIG. 5.
- FIG. 7 shows TLC results under UV light showing DNase I digestion after 3 hours of the oligonucleotide-MPEG conjugate and an oligonucleotide-MPEG conjugate treated with NH 4 OH to chemically remove the MPEG550.
- FIG. 8 shows TLC results under UV light (left) and vanillin stained (right) showing DNase I digestion after 48 hours of functional K-ras sequence, functional K-ras sequence treated with an alkyne-containing reagent, and functional K-ras sequence conjugated with approximately one stoichiometric equivalent of MPEG ⁇ k, functional K-ras sequence conjugated with approximately six stoichiometric equivalents of MPEG ⁇ k, and functional K-ras sequence conjugated with a large stoichiometric excess of MPEG ⁇ k.
- FIG. 9 shows TLC results under UV light (left) and vanillin stained (middle) showing DNase I digestion after one hour of polymerase chain reaction ("PCR") primer (control), PCR primer (digest), a PCR primer-MPEG550 conjugate of the disclosure, and PCR primer-MPEG550 networked conjugate of the disclosure; and shows gel electrophoresis results (right) in a 1% agarose gel showing the PCR amplification products of PCR primer (unmodified 8F primer), PCR primer-MPEG550 conjugate, and PCR primer-MPEG550 conjugate treated with NH 4 OH for either 15 minutes and 18 hours to chemically remove the MPEG550.
- PCR polymerase chain reaction
- FIG. 10 shows TLC results under UV light (left) and vanillin stained (right) showing Sl Nuclease digestion after 30 minutes of Salmon sperm ("SS") DNA (control) and a SS DNA-MPEG550 conjugate of the disclosure.
- FIG. 11 shows TLC results under UV light showing Fetal Calf Serum ("FCS") digestion after 36 hours with samples including a functional p53 siRNA (control), a functional p53 siRNA-MPEG550 conjugate of the disclosure (control), a functional p53 siRNA (digest), and a functional p53 siRNA-MPEG550 conjugate of the disclosure (digest).
- FCS Fetal Calf Serum
- the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.
- a group such as an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or alkoxy group, may be substituted with one or more substituents independently selected from, e.g.
- Biocompatible refers to being compatible with a living tissue, by virtue of, e.g., low or no toxicity, or no immunological rejection.
- a polymer is biocompatible if it has good safety ratio or therapeutic index or protective index.
- a polymer is biocompatible if it has been approved for use in humans by any regulatory agency, such as the FDA or EMEA.
- Biomolecule means any organic molecule.
- a biomolecule is an organic molecule produced by a living organism or an analog or derivative thereof.
- a biomolecule can include a biomolegical molecule.
- Biomolecules include, but are not limited to, lipids, phospholipids, glycolipids, sterols, vitamins, hormones, neurotransmitters, carbohydrates, sugars, disaccharides, amino acids, nucleotides, nucleosides, polynucleotides, saccharides (mono-, poly-, or oligo-saccharides), peptides, polypeptides, proteins, nucleic acids (e.g., ribonucleic acids (RNA), deoxyribonucleic acids (DNA), as well as nucleic acid analogs thereof and polymeric forms thereof), lignin, and mixed groups thereof.
- RNA ribonucleic acids
- DNA deoxyribonucleic acids
- a biomolecule includes a peptide, polypeptide, protein, lipid, sugar, polysaccharide, nucleic acid, nucleotides, or polynucleotides, as well as well as derivatives of the above comprising amino acid or nucleotide analogs or other non-nucleotide groups.
- Biomolecule encompasses those in which the conventional polynucleotide backbone has been replaced with a non-naturally occurring or synthetic backbone, and those in which one or more of the conventional bases has been replaced with a synthetic base capable of participating in Watson-Crick type hydrogen bonding interactions.
- Polynucleotides include single or multiple strand configurations, where one or more of the strands may or may not be completely aligned with one another.
- Nucleic acid analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotriesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), locked-nucleic acids (LNAs), and the like.
- a biomolecule is cDNA, siRNA, microRNA, short hairpin RNA, piwi- interacting RNAs (piRNAs), mitrons, antisense molecules, or another oligonucleotide.
- a "nucleotide” refers to a subunit of a nucleic acid and includes a phosphate group, a 5 carbon sugar and nitrogen containing base, as well as analogs of such subunits.
- An "oligonucleotide” generally refers to a nucleotide multimer of about 10 to 100 nucleotides in length, while a “polynucleotide” includes a nucleotide multimer having any number of nucleotides.
- Degradable means covalent bonds capable of being broken via hydrolysis (reaction with water) under basic or acid conditions, via metabolic pathways, enzymatic degradation (by environmental and/or physiological enzymes), or other biological processes (such as those under physiological conditions in a vertebrate, such as a mammal).
- a degradable bond includes, but is not limited to, carboxylate esters, phosphate esters, carbamates, anhydrides, acetals, ketals, imines, orthoesters, thioesters, or carbonates.
- “Targeting group” means those moieties that have been shown to influence the accumulation of a biomolecule in specific cells. Targeting groups can be comprised of a variety of proteins, peptides, small molecules, or the like. Non-limiting examples include vitamin D and folate (e.g., for cancer cells).
- biomolecule-polymer conjugate(s) of the disclosure are illustrated in Formula
- the linker L is independently a 1 - 20 atom linear or branched linker; the polymer is independently a biocompatible polymer; X is independently an atom of attachment to the biomolecule that is O, NH, NR, or S, where R is part of the biomolecule; n is an integer; and the X — L bond is degradable.
- the loose bond between "L” and the triazole in Formula 1 indicates that the linker "L” can be bound to either carbon of the triazole ring.
- the biomolecule of Formula 1 is a nucleotide, nucleic acid, polynucleotide, amino acid, peptide, polypeptide, protein, or polysaccharide.
- the biomolecule of Formula 1 is a DNA, RNA, peptide, polypeptide, protein, polysaccharide, nucleic acid, nucleotide, amino acid, or polynucleotide.
- the biomolecule is an RNA or DNA oligonucleotide, for example an antisense RNA or DNA oligonucleotide.
- the biomolecule is an siRNA.
- the biomolecule is a mixed group of any of the above.
- the biomolecule is an RNA or DNA oligonucleotide.
- the biomolecule is siRNA, mRNA, mitron, microRNA, or antisense.
- the oligonucleotide comprises from about 2 to about 30 bases, from about 5 to about 25 base pairs, or from about 10 to about 25, or from about 15 to about 25 bases.
- the polymer of Formula 1 is a biocompatible polymer. In certain embodiments, the polymer imparts a stabilizing effect on the biomolecule. When n is greater than 1, the various polymers of Formula 1 can be the same or different. In various embodiments, the polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof. In various embodiments, the polymer is a homopolymer, a block copolymer, or a random copolymer. In certain embodiments, the polymer is polydisperse or monodisperse. In various embodiments, the polydispersity index of the polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the polymer is linear. In certain embodiments the polymer is branched.
- the polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolef ⁇ n, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene,
- PEG polyethylene glycol
- a polyether
- the polymer of Formula 1 has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500.
- the polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000.
- the polymer has an average molecular weight of from about 500 to about 5,000.
- the polymer is independently terminated with a nonfunctional group, such as methyl or methoxy, or a functional group, such as a targeting group.
- a targeting group is a folate.
- the polymer is terminated with another biomolecule.
- the biomolecule - polymer conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
- the linker "L" can of varying lengths and composition.
- the linker is from about 1 to about 20 atoms in length, from about 1 to about 15 atoms in length, from about 1 to about 10 atoms in length, or from about 1 to about 5 atoms in length. In certain embodiments, the linker is 1, 2, 3, 4, 5, or 6 atoms in length. In a particular embodiment, the linker is 3 atoms in length. In various embodiments, the atoms comprising the linker backbone are independently carbon, oxygen, nitrogen, or sulfur.
- the linker L is: — C(O)O(CH 2 ) q — , where q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4. In various sub-embodiments, q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In a particular sub-embodiment, q is 2. In various sub- embodiments, each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S.
- the L — X bond is degradable.
- the degradable L — X bond is a carbonate bond, a carboxylate ester bond, a phosphate ester bond, an anhydride bond, an acetal bond, a ketal bond, an imine bond, an orthoester bond, a thioester bond a carbamate bond, a urea bond, an amide bond.
- the L — X bond in a carbonate or carbamate bond.
- n is from about 1 to about 100, from about 1 to about 75, from about 1 to about 50, from about 1 to about 30 or from about 1 to about 20. In certain embodiments, n is from about 1 to about In various embodiments, n is from about 11 to about 30, from about 13 to about 27, from about 15 to about 25, or from about 17 to about 22. In various other embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, or 25. In a particular embodiment, n is from about 11 to about 14. [0049] In certain embodiments, the biomolecule-polymer conjugate of the disclosure is degradable.
- the biomolecule-polymer conjugate may be initially stable for a period of time when introduced into a living system. This allows time for biomolecule-polymer conjugate to traverse harsh environments, such as the intestinal tract, circulatory system and liver, where the biomolecule alone could be trapped or degraded.
- the degradable nature of the biomolecule-polymer conjugate allows for the release of the biomolecule to the respective site of action in a living system full intact.
- the delay of degradation of the biomolecule-polymer conjugate allows for distribution to a variety of tissues and organs that would be less accessible by the biomolecule alone.
- the biomolecule-polymer conjugate may also allow for slow release of the biomolecule dependent on the rate of degradation.
- the biomolecule-polymer conjugate degrades in vivo to release the biomolecule with a half- life of less than about 2 weeks, less then about 1 week, less than about 2 days, less than about 1 day, less than about
- the biomolecule-polymer conjugate of the disclosure has enhanced stability compared to the corresponding unmodified biomolecule, for example in vivo stability as evidenced by, for example, circulation half-life.
- the biomolecule is released from the protecting polymer layer via degradation of a bond, e.g., the L — X bond, through which the biomolecule is conjugated to the polymer.
- the degradation occurs via hydrolysis
- the degradation process provides an auto-catalytic effect.
- release of the biomolecule may involve the degradation of a biodegradable linker, or digestion of the polymer into smaller, non-polymeric subunits.
- Two different areas of biodegradation may occur: the cleavage of bonds in the polymer backbone which generally results in monomers and oligomers of the polymer; or the cleavage of a bond connecting the polymer to the biomolecule.
- the release of the biomolecule e.g., the degradation of a bond linking the biomolecule to the polymer
- the degradation rate can be measured both in vitro by known methods, for example by UV- Vis spectroscopy, or in vivo, by sampling blood serum over time and determining the concentration of the metabolits by known methods, for example HPLC.
- the degradation rates of a bond linking the biomolecule to the polymer (such as the L — X bond) and of the polymer itself may vary.
- the biomolecule-conjugate of the disclosure is useful for the treatment or prevention or amelioration of a disease, for the modulation of protein/mRNA expression, or as a diagnostic tool.
- composition comprising a biomolecule-polymer conjugate(s) as described herein and a carrier.
- a method of preparing the biomolecule- polymer conjugates of Formula 1 comprises (a) reacting the biomolecule with an alkyne-containing electrophilic reagent, and (b) reacting the alkyne-modif ⁇ ed biomolecule with an azide-containing polymer or mixture of azide-containing polymers.
- the reaction is illustrated in Scheme 1 below:
- steps (a) and (b) are conducted as a "one-pot" synthesis, without isolation and/or purification of the intermediate alkyne-modified biomolecule. In other embodiments, steps (a) and (b) are conducted with isolation and/or purification of the intermediate alkyne-modified biomolecule.
- step (a) of the method the biomolecule is reacted with an alkyne-containing electrophilic reagent to yield an L — X bond.
- the alkyne-containing electrophilic reagent is a carboxylic acid, an acid halide, a carboxylic acid anhydride, a carboxylic acid salt, a carboxylic acid ester, an isocyanate, a carbonate, a carbamate, or a chloroformate.
- the alkyne-containing electrophilic reagent is
- q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4.
- q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S.
- the alkyne-containing electrophilic reagent is a chloroformate, such as propargyl chloroformate.
- step (a) of the method proceeds via one or more of the following reactions (where R is the biomolecule, and X is either OH or NH 2 ): Alcohol + propargyl Chloride, condensation reaction yields an carbonate bond
- Step (a) of the can be conducted in a variety of solvents.
- the first step of the method is conducted in water, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, ether, or a mixture thereof.
- the first step of the method is conducted in a mixture of water and one or more of tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, or ether.
- the reaction is conducted in the absence of water. In other embodiments, the reaction is conducted in water.
- step (a) of the method is conducted in the presence of a base.
- the base is a tertiary alkyl amine, an aromatic amine, a carbonate, or a hydroxide.
- the base is diisopropylethylamine, triethylamine, pyridine, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, or potassium hydroxide.
- Step (a) of the method can be conducted at a variety of temperatures and times, provided that the biomolecule is not degraded.
- the reaction is conducted at a temperature from about -30 0 C to about 25 0 C, from about 0 0 C to about 25 0 C, or from about 5 0 C to about 20 0 C. In certain embodiments, the reaction is conducted for from about 5 minutes to about 8 hours, from about 5 minutes to about 1 hour, from about 20 minutes to about 40 minutes.
- the biomolecule is treated with from about 0.001 to about 1000 molar equivalents of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule. In various embodiments, the biomolecule is treated with from about 0.001 to about 1, from about 0.01 to about 1, from about 0.1 to about 1, or from about 0.5 to about 1 molar equivalent of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule.
- the biomolecule is treated with from about 1 to about 1000, from about 1 to about 500, from about 1 to about 100, from about 1 to about 10,or from about 1 to about 5 molar equivalents of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule.
- the biomolecule can be treated prior to step (a) of the method.
- the pre-treatment is a desalting, denaturing, or splitting double stranded molecules into single strands.
- the alkyne-modified biomolecule is reacted with one or a mixture of azide-containing polymers.
- the azide-containing polymer can be any biocompatible polymer with an azide group. In certain embodiments, the azide-containing polymer imparts a stabilizing effect on the biomolecule.
- n is greater than 1, the various polymers of Formula 1 can be the same or different.
- the azide- containing polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof.
- the azide-containing polymer is a homopolymer, a block copolymer, or a random copolymer.
- the azide-containing polymer is polydisperse or monodisperse. In various embodiments, the polydispersity index of the azide-containing polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the azide-containing polymer is linear. In certain embodiments the azide-containing polymer is branched.
- the azide-containing polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolef ⁇ n, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a
- the azide-containing polymer has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500.
- the azide-containing polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000.
- the azide- containing polymer has an average molecular weight of from about 500 to about 5,000.
- the azide-containing polymer is independently terminated with a non-functional group, such as a methyl or methoxy, or a functional group, such as a targeting group.
- the targeting group is a folate.
- the azide-containing polymer is a mixture of non-functional terminated and functional terminated polymers.
- the mixture is a mixture of methoxy terminated and folate-terminated polymers, for example a mixture of methoxy- terminated PEG and folate-terminated PEG.
- the polymer is terminated with another biomolecule.
- the biomolecule -polymer conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
- Step (b) of the method can be conducted in a variety of solvents.
- step (b) of the method is conducted in methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, ether, water, or a mixture thereof.
- step (b) of the method is conducted in a mixture of water and one or more of methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, or ether.
- step (b) of the method is conducted in water.
- Step (b) of the method can be conducted at a variety of temperatures and times, provided that the biomolecule is not degraded.
- the reaction is conducted at a temperature from about -30 0 C to about 70 0 C, from about 0 0 C to about 65 0 C, or from about 25 0 C to about 65 0 C.
- the reaction is conducted for from about 1 minute to about 8 hours, from about 5 minutes to about 3 hour, or from about 20 minutes to about 60 minutes.
- step (b) of the method is conducted in the presence of a catalyst, for example in the presence of a copper catalyst.
- the copper catalyst is copper bromide or copper iodide.
- step (b) of the method is conducted in presence of a mixture of copper(II), e.g., copper(II) sulfate, and a reducing agent, e.g., sodium ascorbate.
- step (b) of the method is conducted in the absence of a catalyst, for example in the absence of a metal catalyst such as copper.
- the absence of a catalyst such as a copper catalyst may be particularly advantageous as the produced biomolecule-polymer conjugate is substantially free of copper.
- the copper-free method produced a biomolecule-polymer conjugate that contains less than about 100 ppm copper, less than about 10 ppm copper, or less than about 1 ppm copper.
- the method further comprises (c) purifying the biomolecule-polymer conjugate.
- the conjugate is purified by size exclusion chromatography, reverse phase chromatography, thin layer chromatography, ion exchange chromatography, column chromatography, precipitation, or liquid-liquid extraction.
- the conjugate is purified size exclusion chromatography.
- modifiable nucleotides i.e., adenine, guanine, cytosine, and uracil
- Formula 2 modifiable nucleotides
- the reactive groups on the RNA include, but are not limited to, primary amines (i.e., where X in Formula 1 is NH), secondary amines (i.e., where X in Formula 1 is NR), and hydroxyl groups (i.e., where X in Formula 1 is O). In certain embodiments, only the primary amines and hydroxyl groups are modifiable. Secondary amines on natural RNAs are generally less reactive than primary amines, and thus may not always be modified in accordance with the method of the disclosure.
- the reactive moieties on the RNA nucleotides can be reacted with propargyl chloroformate.
- This reaction may be undertaken in a variety of different solvents or solvent mixtures. This reaction may also be undertaken in the presence or absence of bases, acids, acid scavengers, water scavenger, or drying reagents.
- Formula 3 illustrate the modification of all reactive groups in each of the nucleotides. In other embodiments, the nucleotides are incompletely modified.
- the RNA comprises from about 1 to about 50, from about 5 to about 40, from about 10 to about 35, from about 10 to about 20, from about 20 to about 35, from about 10 to about 15, from about 15 to about 20, from about 20 to about 25, from about 25 to about 30, and from about 30 to about 35 alkyne groups after step (a) of the method.
- Formula 4 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and the alkyne appended to an adenine.
- the alkyne group reacts with an azide end group of a polymer chain to form a triazole linkage.
- the resulting biomolecule-polymer conjugate exhibits a regioisomerism, that is there are two regioisomers formed at the triazole. This regioisomerism is illustrated by the loose bond in Formula 1.
- Formula 5 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and two alkyne groups appended to an adenine.
- an azide-containing polymer e.g., PEG azide terminated with a methoxy group or a targeting group
- alkyne groups reacts with an azide end group of a polymer chain to form more than one triazole linkage
- the resulting biomolecule- polymer conjugate exhibits a regioisomerism, that is there are two regioisomers formed at each triazole.
- four regioisomers may be formed.
- Formula 6 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and one or two alkyne groups appended to guanine, cytosine, and uracil.
- an azide-containing polymer e.g., PEG azide terminated with a methoxy group or a targeting group
- alkyne groups appended to guanine, cytosine, and uracil.
- the modification of these nucleotides can embody single or multiple linkers to one or more polymer chains by forming one or more triazole rings as is illustrated in Formula 6.
- the modification of the RNA may occur at the sugar hydroxyl only, as illustrated in Formula 7. Without intending to be limited by mechanism, it is believed that this mode of modification occurs for double-stranded oligonucleotides, where the base pairing precludes modification of the base itself.
- Formula 7 Alkyne-modified RNA nucleotides (sugar hydroxyl only)
- the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, and only the sugar hydroxyl has been alkyne-modif ⁇ ed
- Formula 8 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and the alkyne group appended to adenine, guanine, cytosine, and uracil.
- an azide-containing polymer e.g., PEG azide terminated with a methoxy group or a targeting group
- RNA nucleotide-polymer conjugates (sugar hydroxyl only)
- the above-described method is analogously applied to DNAs.
- Natural DNA incorporated thymine which, in embodiments where the biomolecule is a DNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, can be modified to form the product illustrated in Formula 9.
- kits may be analogously applied to biomolecules besides DNAs and RNAs, as described above.
- kits suitable for preparing the biomolecule- polymer conjugate of the disclosure comprising an alkyne-containing electrophilic reagent in a first container, an azide-containing biocompatible polymer in a second container, and instructions for their use.
- the alkyne-containing electrophilic reagent is a carboxylic acid, an acid halide, a carboxylic acid anhydride, a carboxylic acid salt, a carboxylic acid ester, an isocyanate, a carbonate, a carbamate, or a chloro formate.
- the alkyne-containing electrophilic reagent is
- q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4.
- q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S.
- the alkyne-containing electrophilic reagent is a chloroformate, such as propargyl chloroformate
- the azide-containing polymer can be any biocompatible polymer with an azide group. In certain embodiments, the azide-containing polymer imparts a stabilizing effect on the biomolecule. When n is greater than 1, the various polymers of Formula 1 can be the same or different. In various embodiments, the azide-containing polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof. In various embodiments, the azide-containing polymer is a homopolymer, a block copolymer, or a random copolymer. In certain embodiments, the azide-containing polymer is polydisperse or monodisperse.
- the polydispersity index of the azide-containing polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the azide-containing polymer is linear. In certain embodiments the azide-containing polymer is branched.
- the azide-containing polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefm, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cell
- the azide-containing polymer has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500.
- the azide-containing polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000.
- the azide- containing polymer has an average molecular weight of from about 500 to about 5,000.
- the azide-containing polymer is independently terminated with a non-functional group, such as a methyl or methoxy, or a functional group, such as a targeting group.
- the targeting group is a folate.
- the azide-containing polymer is a mixture of non-functional terminated and functional terminated polymers.
- the mixture is a mixture of methoxy terminated and folate-terminated polymers, for example a mixture of methoxy- terminated PEG and folate-terminated PEG.
- the polymer is terminated with another biomolecule.
- the biomolecule -polymer conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
- the first container further comprises a first solvent.
- the first solvent is water, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, ether, or a mixture thereof.
- the first solvent is a mixture of water and one or more of tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, or ether.
- the first container does not comprise water.
- the first solvent is water.
- the second container further comprises a second solvent.
- the second solvent is methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, ether, water, or a mixture thereof.
- the second solvent is water and one or more of methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, or ether.
- the second solvent is water.
- the kit optionally further comprises one or more containers comprising the following: a base, a metal catalyst, a solvent, a purification column, a filter, a drying agent, a mixing vessel, a magnetic stirbar, and a filtration vessel.
- the kit comprises instructions to (1) dissolve the biomolecule in a first solvent (optionally provided with the kit); (2) add the alkyne-containing electrophilic reagent to the solution of the biomolecule; (3) optionally add a base to the solution of the biomolecule and alkyne-containing electrophilic reagent; (4) stir for between 30 minutes and 8 hours, or for between 1 hour and 2 hours; (5) remove solvent, alkyne- containing electrophilic reagent, and optional base; (6) dissolve the alkyne-modified biomolecule in a second solvent (optionally provided with the kit); (7) add the azide- containing polymer; (8) optionally add the metal catalyst; (8) stir for between 1 and 24 hours, or for about 2 hours, at room temperature or at a temperature from 35 0 C to about 80 0 C; (9) optionally concentrate the reaction mixture; (10) optionally purify using filter or column (optionally provided with the kit).
- the final product of the kit may be used in a cell based assay or
- a model oligonucleotide 5 ' -TTTT ATTTTATTTT ATTTT A-3 ' (SEQ ID NO: 1), can be modified according to the method of the disclosure.
- the model oligonucleotide (1 mg) is dissolved in 20 ⁇ L of dimethyl formamide (DMF) at room temperature.
- DMF dimethyl formamide
- propargyl chloro formate (1.8 ⁇ L)
- the reaction mixture is allowed to stir for 2 hours.
- the reaction mixture is then concentrated under N 2 and the residue analyzed by
- FIG. IA only shows alkyne modification at one site, it is understood that such modification may occur at every modifiable site on the biological molecule. Therefore, in the model oligonucleotide, alkyne modification may occur at every adenine site.
- FIG. IB shows an oligonucleotide segment in which each nucleic acid base is alkyne-modified.
- FIG. 2 illustrates an embodiment of the method using methoxy-terminated PEG-azide and a biomolecule modified with propargyl chloroformate or the like.
- the method of the disclosure can be conducted as a "one -pot" reactions without isolation or cleaning of the products from the alkyne modification reaction.
- a representative reaction is as follows: the alkyne-modified biomolecule is dissolved in 30 ⁇ L of DMF. PEG azide is added to this mixture and the reaction mixture is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N 2 and analyzed by NMR spectroscopy.
- FIG. 3 A illustrates an embodiment of the method. Using click chemistry, the biomolecule, in this case siRNA, is alkyne -modified at several locations along the nucleotide sequence. Several azide functional PEG chains are attached to the modified siRNA at the alkyne modification sites via the click reaction, creating an siRNA-polymer conjugate comprising multiple PEG strands.
- Hemoglobin (1 mg) is dissolved in 30 ⁇ L of DMF at room temperature. To this mixture is added propargyl chloro formate (1.8 ⁇ L), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N 2 and the residue analyzed by
- NMR spectroscopy It is understood that such modification may occur at every modifiable site on the biological molecule, for example at a cysteine SH (e.g., Cys34).
- the alkyne- modified hemoglobin is then dissolved in 30 ⁇ L of DMF.
- PEG azide (10 ⁇ L) is added to this mixture and the reaction is allowed to stir for 2 hours at room temperature.
- the reaction mixture is concentrated under N 2 and analyzed by NMR spectroscopy.
- FIG. 3B illustrates an embodiment of the method.
- the biomolecule in this case hemoglobin, is modified at several locations.
- Azide-containing molecules e.g., homopolymers, copolymers, or other small molecules
- the modified biomolecule is modified at several locations.
- Azide-containing molecules e.g., homopolymers, copolymers, or other small molecules
- Hemoglobin is useful as a blood substitute, and thus the hemoglobin-polymer conjugates of the disclosure may be useful as prodrugs of hemoglobin. See, e.g., P. W.
- polysaccharide chitosan (1 mg) is dissolved in 20 ⁇ L of DMF at room temperature. To this mixture is added propargyl chloroformate (2 ⁇ L), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N 2 and the residue analyzed by NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, such as a glucosamine NH 2 or
- Chitosan may be useful for the treatment of various diseases, for example those characterized by over-expression of folic acid receptor cells, and thus chitosan-polymer conjugates of the disclosure may be useful as prodrugs of chitosan. See, e.g., U.S. Patent
- nucleotide adenosine triphosphate (ATP) (lmg) is dissolved in 30 ⁇ L of DMF at room temperature. To this mixture is added propargyl chloroformate (1 ⁇ L), and the reaction is allowed to stir for 2 hours. The reaction mixture is then concentrated under N 2 and the residue analyzed by NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, for example a sugar OH or the adenine NH 2 .
- the alkyne-modified nucleotide from the modification reaction is dissolved in
- FIG. 3B is also representative of this reaction.
- RNA or DNA oligonucleotide (0.1 mg) is dissolved in 20 ⁇ l of tetraethylene glycol dimethylether at room temperature. This is followed by the addition of 5 to 20 ⁇ l of diisopropylethylamine at room temperature. Propargyl chloroformate (0.5 ⁇ l) is then added, and the reaction mixture is allowed to stir for approximately 30 minutes. All volatile components are removed. Methanol (20 ⁇ l) is added. The azide-containing polymer (1 to 3 ⁇ l or 1 to 3 mg) is added and the reaction mixture stirred for approximately 1 hour. All volatiles are removed. The resulting product is then analyzed by HPLC.
- Example 8 Preparation of Azide-Containing Polymer Terminated with a Targeting Group
- the carboxylic acid of folate 300mg is first activated by reacting with N- hydroxysuccimide (NHS) and N ⁇ '-Dicyclohexylcarbodiimide (DCC) in dimethyl sulfoxide (DMSO) stirred for 18 hours, filtered and washed with 30% acetone-ether to give the corresponding activated ester.
- This activated ester is then dissolved in dry pyridine and stirred with monoamine PEG azide for 18 hours. The pyridine is evaporated and the resulting mixture chromatographed to give the folate functionalized PEG azide.
- FIG. 3 C illustrates an embodiment of the disclosure where the alkyne-modified biomolecule (e.g., siRNA) is conjugated to an azide-containing polymer terminated with a functional group such as a targeting group.
- the azide-containing polymers terminated with a functional group are conjugated to the alkyne-modified sites on the biomolecule via the click reaction, creating a biomolecule-polymer conjugate comprising multiple polymer strands terminated with a functional group.
- polymer chains e.g., PEG
- a copolymer having multiple azide functional sites A
- the copolymer includes cationic groups along the backbone (B).
- the polymer chains (e.g., PEG) of varying lengths can also be bonded to a multifunctional azide homopolymer segment (C).
- An alkyne-modified biomolecule is then conjugated to the polymer having multiple azide groups (A, B, or C), via the click reaction, to form a network of biomolecules and polymers (D).
- the additional azide functionalities on the polymers allows each polymer to form bonds with multiple biomolecules creating a network of bonded biomolecules and polymers.
- Nucleases and proteases are common and result in extremely short half-life for biomolecules not protected from the in vivo environment.
- carboxylesterases (CES) are known to be present in many cancerous tumor cells. Therefore, the ability of the biomolecule-polymer conjugates of the disclosure to withstand degradation in the presence of fetal calf serum (FCS) and either DNase I, or Sl nuclease is investigated, as well as the ability of carboxylesterase 1 to degrade the biomolecule-polymer conjugates and release the biomolecule.
- FCS fetal calf serum
- DNase I DNase I
- Sl nuclease Sl nuclease
- FIG. 5 shows TLC results under UV light showing DNase I digestion after one hour of the model oligonucleotide of Example 1 conjugated to MPEG550 (methoxy-terminated PEG, MW 550), the model oligonucleotide alone, and a blend of the model oligonucleotide and MPEG550. As shown in FIG.
- FIG. 6 shows TLC results under UV light showing DNase I digestion after six hours of the model oligonucleotide and the oligonucleotide-MPEG conjugate.
- the native model oligonucleotide was completely digested after 6 hours while the oligonucleotide-MPEG conjugate remained intact.
- Example 11 Functional Sequence Results K-ras
- the functional K-ras was modified according to the method of Example 7 using MPEG ⁇ k (methoxy-terminate PEG, MW 6000) at low (one equivalent MPEG ⁇ k, i.e., n is about 1), medium (six equivalents MPEG ⁇ k, i.e., n is about 6), and high substitution (excess MPEG ⁇ k, i.e., n is about 11 - 30), and evaluated for stability in the presence of DNase I.
- MPEG ⁇ k methoxy-terminate PEG, MW 6000
- FIG. 9 shows TLC results under UV light (left) and vanillin stained (middle) showing DNase I digestion after one hour of PCR primer (control), PCR primer (digest), the MPEG550 conjugate, and the MPEG550-networked-conjugate.
- control control
- PCR primer digest
- the MPEG550 conjugate and the MPEG550-networked-conjugate were resistant to nuclease degradation.
- Each 50- ⁇ l PCR mixture contained 1 ⁇ l template DNA (either E. coli. or an environmental isolate belonging to the genus Streptomonospora), 2 U Taq DNA polymerase (Eppendorf ), Ix Taq buffer, 2.75 ⁇ M Mg(OAc) 2 , Ix Taq Master PCR Enhancer, each deoxynucleoside triphosphate at a concentration of 20 ⁇ M , and each primer at a concentration of 0.4 ⁇ M.
- template DNA either E. coli. or an environmental isolate belonging to the genus Streptomonospora
- Eppendorf U Taq DNA polymerase
- Ix Taq buffer 2.75 ⁇ M Mg(OAc) 2
- Ix Taq Master PCR Enhancer each deoxynucleoside triphosphate at a concentration of 20 ⁇ M
- each primer at a concentration of 0.4 ⁇ M.
- FIG. 8 shows gel electrophoresis results in a 1% agarose gel showing the PCR amplification products of PCR primer (unmodified 8F primer), MPEG550 conjugate, and the MPEG550 conjugate cleaved in NH 4 OH for 15 minutes and 18 hours. It was found that the MPEG550 conjugates were functional and yielded the appropriate size amplification product, as did the NH 4 OH treated MPEG550 conjugate, however no amplification product was detected for the MPEG550- networked-conjugate. Nevertheless, FIG. 9 also shows that the MPEG550 conjugate and MPEG550-networked-conjugate show excellent protection when exposed to DNase I over the unmodified PCR primer.
- Example 13 Functional Sequence Results Salmon Sperm DNA: [0121] Salmon sperm (SS) DNA was used as an example biomolecule. An SS- MPEG550 conjugate was prepared according to Example 7 and digested with Sl Nuclease. FIG. 10 shows TLC results under UV light (left) and vanillin stained (right) showing Sl Nuclease digestion after 30 minutes of SS DNA (control) and SS-MPEG550 conjugate. As can be seen in FIG. 10, when exposed to the very aggressive Sl Nuclease, the SS-MPEG550 conjugate is stable while the native SS DNA is almost completely digested.
- Example 14 Functional Sequence Results siRNA
- FIG. 11 shows TLC results under UV light showing FCS digestion after 36 hours with samples including siRNA (control), siRNA- MPEG550 conjugate (control), siRNA (digest), and siRNA-MPEG550 conjugate (digest).
- siRNA-MPEG550 conjugate As can be seen in FIG. 11, when the siRNA-MPEG550 conjugate is exposed to 30% FCS for 36 hours, conditions in which the siRNA alone is completely degraded, the siRNA-MPEG550 conjugate remains stable.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed herein are biomolecule-polymer conjugates of Formula 1, as well as methods of preparing same and kits for preparing same.
Description
BIOMOLECULE-POLYMER CONJUGATES AND METHODS OF MAKING SAME
[0001] This application claims the benefit of U.S. Provisional Application No. 61/182,838, filed June 1, 2009, which is herein incorporated by reference in its entirety. Background
[0002] Recent advancements in the identification of biologically relevant targets has led to the discovery of pharmaceutically and/or therapeutically useful biomolecules, for examples small biomolecules (lipids, phospholipids, glycolipids, sterols, vitamin, hormones, neurotransmitters, carbohydrates, sugars, disaccharides, natural products), bimolecular monomers (amino acids, nucleotides, monosaccharides), and bimolecular polymers (peptides, oligopeptides, polypeptides, proteins, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), oligosaccharides, polysaccharides, and lignin). For example, selective genetic modifying agents such as small interfering RNA (siRNA) and micro RNA (mRNA) have been proposed and developed. Though the identification of biologically relevant targets has grown considerably, significant issues have plagued the use of such biomolecules, particularly the ability to provide degradative stability, deliver such biomolecules to their site of action in vivo, and recover efficacy.
[0003] Among the particular problems is the instability of the biomolecules. Such biomolecules are generally susceptible to environmental degradation in vitro and enzymatic degradation in vivo. Furthermore, the inability to selectively deliver the biomolecules to their site of action has limited their therapeutic utility.
[0004] Attempts to solve these pervasive problems have been plagued with further problems. For example, attempts have been made to chemically modify the biomolecules to prevent degradation, to make use of viral technology to provide site-specific delivery, and to encapsulate the biomolecules within polymer structures. These attempted solutions, however, typically lower the efficacy of the biomolecules, cause significant toxic side effects, or fail to achieve the site-specific delivery required to achieve efficacious results. The solution of this vexing problem would thus address a longfelt need in the field of biomolecular pharmaceutics.
[0005] The problems discussed above are particularly relevant in the field of small interfering RNA (siRNA). Small interfering RNA refers to RNA oligonucleotides that modulate protein expression. Small interfering RNAs offer great potential in the treatment of numerous diseases, such as cancer, but have failed to reach their full potential due to an
inability to reach the site of action in an active form. See R. James Christie et al Endocrinology, 2010, 151(2), 466-473.
[0006] RNA interference (RNAi) generally refers to a pathway in eukaryotic cells for sequence-specific targeting and cleavage of complementary messenger RNA. See S. M. Elbashir et al., Nature, 2001, 411, 494-498. This is accomplished through the delivery of complementary strands of DNA or RNA into cells, complexation of these strands with proteins or enzymes that allow for the degradation or inhibition of mRNA thereby inhibiting cellular mechanisms.
[0007] Currently, there have been no siRNAs successfully commercialized, at least in part because of the delivery problems described above. There are currently two basic technologies for siRNA delivery in clinical trials. The first involves local delivery of an siRNA to the site of action to treat maladies such as age-related macular degeneration (AMD). See K.A. Whitehead, K.A. et al., Nature Reviews Drug Discovery, 2009, 8, 129-138. This technique does not utilize a protective mechanism to prevent the degradation of the siRNA or provide a selective targeting mechanism to increase the specificity of the siRNA delivery, and as such does not address the above-described problems. Indeed, this delivery technology is limited to local administration of therapeutically high doses of the siRNA. [0008] The second technology currently in clinical trials involves the use of viral vectors for siRNA transport. See T.R. Brummelkamp et al., Cancer Cell, 2002, 2(3), 243-247 While it has been found that viral vectors are effective for in vitro delivery, significant additional problems arise from this technology. Specifically, use of viral vectors in early clinical trials has led to multiple adverse side effects and even death. The severity and unpredictability of viral vectors for therapeutic use in the general population has yet to be determined. [0009] A potential solution to the siRNA delivery problem involves the direct modification of the siRNA to prevent environmental and enzymatic degradation. The methods used to date, however, suffer from several drawbacks: although modification can increase the stability, a substantial reduction of efficacy has been observed. [0010] It is thus an object of the disclosure to provide a method of stabilizing biomolecules, for example siRNAs, by modifying the biomolecules to provide biomolecule conjugates that solve the above-described problems. Further, it is an object of the disclosure to provide biomolecule conjugates that have enhanced stability yet retain their efficacy.
Summary
[0011] In one aspect of the disclosure, provided herein is biomolecule-polymer conjugate(s) of Formula 1 :
Formula 1 where the linker L is independently a 1 - 20 atom linear or branched linker; the polymer is independently a biocompatible polymer; X is independently an atom of attachment to the biomolecule that is O, NH, NR, or S, where R is part of the biomolecule; n is an integer from about 1 to about 30; and the X — L bond is degradable. The L — triazole bond can be to either carbon of the triazole ring, and is represented by the loose bond as illustrated in Formula 1. In certain embodiments, the biomolecule of Formula 1 is a nucleotide, nucleic acid, polynucleotide, amino acid, peptide, polypeptide, protein, or polysaccharide. [0012] In another aspect of the disclosure, provided herein is a method of preparing a biomolecule-polymer conjugate(s) of Formula 1. The method comprises: (a) reacting the biomolecule with an alkyne-containing electrophilic reagent, and (b) reacting the alkyne- modified biomolecule with an azide-containing polymer or mixture of azide-containing polymers. The reaction is illustrated in Scheme 1 below:
Q-L^≡ biomolecule XH , biomolecule -X-L- n
Scheme 1 where the polymer, X, L, and n are as defined above, and Q is a leaving group.
[0013] In another aspect of the disclosure, provided herein is a kit suitable for preparing a biomolecule-polymer conjugate(s) of the disclosure, the kit comprising an alkyne-containing
electrophilic reagent in a first container, an azide-containing biocompatible polymer in a second container, and instructions for their use.
[0014] The invention is based, in part, on the surprising and unexpected discovery of biomolecule-polymer conjugates that have increased stability compared to unmodified biomolecules, yet retain their efficacy against their intended target.
[0015] Those skilled in the art will realize that this invention is capable of embodiments that are different from those shown and details of the devices and methods can be changed in various manners without departing from the scope of this invention. Accordingly, the drawings and descriptions are to be regarded as including such equivalent embodiments as do not depart from the spirit and scope of this invention.
Brief Description of Drawings
[0016] For a more complete understanding and appreciation of this invention, and its many advantages, reference will be made to the following detailed description taken in conjunction with the accompanying drawings.
[0017] FIG. IA illustrates an embodiment of the first step of the method described herein, wherein an adenine amino group is reacted with propargyl chloroformate.
[0018] FIG. IB illustrates an embodiment of the first step of the method described herein, illustrating modification of one or more amino and hydroxyl groups of various nucleobases.
[0019] FIG. 2 illustrates an embodiment of the second step of the method described herein, where an alkyne-containing biomolecule, the product of the first step of the method, is reacted with an azide-containing polymer, to form a biomolecule-polymer conjugate(s) of the disclosure.
[0020] FIG. 3A illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an siRNA is conjugated to multiple azide-containing polymers;.
[0021] FIG. 3B illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an alkyne-modified biomolecule is conjugated to multiple azide-containing polymers.
[0022] FIG. 3C illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure where an siRNA is conjugated to multiple azide-containing polymers terminated with a functional group.
[0023] FIG. 4 illustrates an embodiment of a biomolecule-polymer conjugate(s) of the disclosure that is a biomolecule-polymer conjugate network.
[0024] FIG. 5 shows Thin Layer Chromatography ("TLC") results under ultraviolet ("UV") light showing deoxyribonuclease ("DNase") I digestion after one hour of an oligonucleotide-MPEG conjugate prepared from methoxy-polyethylene glycol with an average molecular weight of 550 ("MPEG550"), the unmodified oligonucleotide, and a blend of the unmodified oligonucleotide and MPEG550.
[0025] FIG. 6 shows TLC results under UV light showing DNase I digestion after six hours of the conjugate and unmodified oligonucleotide of FIG. 5.
[0026] FIG. 7 shows TLC results under UV light showing DNase I digestion after 3 hours of the oligonucleotide-MPEG conjugate and an oligonucleotide-MPEG conjugate treated with NH4OH to chemically remove the MPEG550.
[0027] FIG. 8 shows TLC results under UV light (left) and vanillin stained (right) showing DNase I digestion after 48 hours of functional K-ras sequence, functional K-ras sequence treated with an alkyne-containing reagent, and functional K-ras sequence conjugated with approximately one stoichiometric equivalent of MPEGβk, functional K-ras sequence conjugated with approximately six stoichiometric equivalents of MPEGβk, and functional K-ras sequence conjugated with a large stoichiometric excess of MPEGβk. [0028] FIG. 9 shows TLC results under UV light (left) and vanillin stained (middle) showing DNase I digestion after one hour of polymerase chain reaction ("PCR") primer (control), PCR primer (digest), a PCR primer-MPEG550 conjugate of the disclosure, and PCR primer-MPEG550 networked conjugate of the disclosure; and shows gel electrophoresis results (right) in a 1% agarose gel showing the PCR amplification products of PCR primer (unmodified 8F primer), PCR primer-MPEG550 conjugate, and PCR primer-MPEG550 conjugate treated with NH4OH for either 15 minutes and 18 hours to chemically remove the MPEG550.
[0029] FIG. 10 shows TLC results under UV light (left) and vanillin stained (right) showing Sl Nuclease digestion after 30 minutes of Salmon sperm ("SS") DNA (control) and a SS DNA-MPEG550 conjugate of the disclosure.
[0030] FIG. 11 shows TLC results under UV light showing Fetal Calf Serum ("FCS") digestion after 36 hours with samples including a functional p53 siRNA (control), a functional p53 siRNA-MPEG550 conjugate of the disclosure (control), a functional p53 siRNA (digest), and a functional p53 siRNA-MPEG550 conjugate of the disclosure (digest). Detailed Description
[0031] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the event that there is a plurality of definitions for a term used herein, those in this section prevail unless stated otherwise. [0032] The term "about" or "approximately" means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" or "approximately" means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term "about" or "approximately" means within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range.
[0033] The term "optionally substituted" is intended to mean that a group, such as an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, or alkoxy group, may be substituted with one or more substituents independently selected from, e.g. , (a) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q; and (b) halo, cyano (-CN), nitro (-NO2), -C(O)Ra, -C(O)ORa, -C(O)NRbRc, -C(NRa)NRbRc, -ORa, -OC(O)Ra, -OC(O)ORa, -OC(O)NRbRc, -OC(=NRa)NRbRc, -OS(O)Ra, -OS(O)2Ra, -OS(O)NRbRc, -OS(O)2NRbRc, -NRbRc, -NRaC(O)Rd, -NRaC(O)ORd, -NRaC(O)NRbRc, -NRaC(=NRd)NRbRc, -NRaS(O)Rd, -NRaS(O)2Rd, -NRaS(O)NRbRc, -NRaS(O)2NRbRc, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)NRbRc, and -S(O)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen; (ii) Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3-7 cycloalkyl, C6-14 aryl, heteroaryl, or heterocyclyl, each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q. As used herein, all groups that can be substituted are "optionally substituted," unless otherwise specified. [0034] "Biocompatible" refers to being compatible with a living tissue, by virtue of, e.g., low or no toxicity, or no immunological rejection. In certain embodiments, a polymer is biocompatible if it has good safety ratio or therapeutic index or protective index. In certain embodiments, a polymer is biocompatible if it has been approved for use in humans by any regulatory agency, such as the FDA or EMEA.
[0035] "Biomolecule" means any organic molecule. In an embodiment, a biomolecule is an organic molecule produced by a living organism or an analog or derivative thereof. A biomolecule can include a biomolegical molecule. Biomolecules include, but are not limited to, lipids, phospholipids, glycolipids, sterols, vitamins, hormones, neurotransmitters, carbohydrates, sugars, disaccharides, amino acids, nucleotides, nucleosides, polynucleotides, saccharides (mono-, poly-, or oligo-saccharides), peptides, polypeptides, proteins, nucleic acids (e.g., ribonucleic acids (RNA), deoxyribonucleic acids (DNA), as well as nucleic acid analogs thereof and polymeric forms thereof), lignin, and mixed groups thereof. In certain embodiments, a biomolecule includes a peptide, polypeptide, protein, lipid, sugar, polysaccharide, nucleic acid, nucleotides, or polynucleotides, as well as well as derivatives of the above comprising amino acid or nucleotide analogs or other non-nucleotide groups. Biomolecule encompasses those in which the conventional polynucleotide backbone has been replaced with a non-naturally occurring or synthetic backbone, and those in which one or more of the conventional bases has been replaced with a synthetic base capable of participating in Watson-Crick type hydrogen bonding interactions. Polynucleotides include single or multiple strand configurations, where one or more of the strands may or may not be completely aligned with one another. Nucleic acid analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotriesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs), locked-nucleic acids (LNAs), and the like. In some embodiments, a biomolecule is cDNA, siRNA, microRNA, short hairpin RNA, piwi- interacting RNAs (piRNAs), mitrons, antisense molecules, or another oligonucleotide. [0036] A "nucleotide" refers to a subunit of a nucleic acid and includes a phosphate group, a 5 carbon sugar and nitrogen containing base, as well as analogs of such subunits. . An "oligonucleotide" generally refers to a nucleotide multimer of about 10 to 100 nucleotides in length, while a "polynucleotide" includes a nucleotide multimer having any number of nucleotides.
[0037] "Degradable" means covalent bonds capable of being broken via hydrolysis (reaction with water) under basic or acid conditions, via metabolic pathways, enzymatic degradation (by environmental and/or physiological enzymes), or other biological processes (such as those under physiological conditions in a vertebrate, such as a mammal). A degradable bond includes, but is not limited to, carboxylate esters, phosphate esters, carbamates, anhydrides, acetals, ketals, imines, orthoesters, thioesters, or carbonates.
[0038] "Targeting group" means those moieties that have been shown to influence the accumulation of a biomolecule in specific cells. Targeting groups can be comprised of a variety of proteins, peptides, small molecules, or the like. Non-limiting examples include vitamin D and folate (e.g., for cancer cells).
Biomolecule-Polymer Conjugates
[0039] The biomolecule-polymer conjugate(s) of the disclosure are illustrated in Formula
1 :
Formula 1 where the linker L is independently a 1 - 20 atom linear or branched linker; the polymer is independently a biocompatible polymer; X is independently an atom of attachment to the biomolecule that is O, NH, NR, or S, where R is part of the biomolecule; n is an integer; and the X — L bond is degradable. The loose bond between "L" and the triazole in Formula 1 indicates that the linker "L" can be bound to either carbon of the triazole ring. [0040] In certain embodiments, the biomolecule of Formula 1 is a nucleotide, nucleic acid, polynucleotide, amino acid, peptide, polypeptide, protein, or polysaccharide. In certain embodiments, the biomolecule of Formula 1 is a DNA, RNA, peptide, polypeptide, protein, polysaccharide, nucleic acid, nucleotide, amino acid, or polynucleotide. In certain embodiments, the biomolecule is an RNA or DNA oligonucleotide, for example an antisense RNA or DNA oligonucleotide. In a particular embodiment, the biomolecule is an siRNA. In certain embodiments, the biomolecule is a mixed group of any of the above. [0041] In certain embodiments, the biomolecule is an RNA or DNA oligonucleotide. In a specific embodiment, the biomolecule is siRNA, mRNA, mitron, microRNA, or antisense. In certain subembodiments, the oligonucleotide comprises from about 2 to about 30 bases, from about 5 to about 25 base pairs, or from about 10 to about 25, or from about 15 to about 25 bases.
[0042] In certain embodiments, the polymer of Formula 1 is a biocompatible polymer. In certain embodiments, the polymer imparts a stabilizing effect on the biomolecule. When n is greater than 1, the various polymers of Formula 1 can be the same or different. In various
embodiments, the polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof. In various embodiments, the polymer is a homopolymer, a block copolymer, or a random copolymer. In certain embodiments, the polymer is polydisperse or monodisperse. In various embodiments, the polydispersity index of the polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the polymer is linear. In certain embodiments the polymer is branched.
[0043] In certain embodiments, In certain embodiments, the polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefϊn, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cellulosic, a starch, a naturally occurring polymer, a poly(vinyl imidazole), a polyacetal, a polysulfone, a chlorosulphonate polyolefϊn, or a blend or copolymer thereof. In a particular embodiment, the polymer is PEG.
[0044] In various embodiments, the polymer of Formula 1 has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500. In various embodiments, the polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000. In a particular embodiment, the polymer has an average molecular weight of from about 500 to about 5,000.
[0045] In certain embodiments, the polymer is independently terminated with a nonfunctional group, such as methyl or methoxy, or a functional group, such as a targeting group. In a particular embodiment, the targeting group is a folate. In certain embodiments, the polymer is terminated with another biomolecule. In such an embodiment, the biomolecule - polymer conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
[0046] The linker "L" can of varying lengths and composition. In certain embodiments, the linker is from about 1 to about 20 atoms in length, from about 1 to about 15 atoms in length, from about 1 to about 10 atoms in length, or from about 1 to about 5 atoms in length. In certain embodiments, the linker is 1, 2, 3, 4, 5, or 6 atoms in length. In a particular embodiment, the linker is 3 atoms in length. In various embodiments, the atoms comprising the linker backbone are independently carbon, oxygen, nitrogen, or sulfur. In a particular embodiment, the linker L is: — C(O)O(CH2)q — , where q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4. In various sub-embodiments, q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In a particular sub-embodiment, q is 2. In various sub- embodiments, each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S.
[0047] In certain embodiments, the L — X bond is degradable. In certain sub- embodiments, the degradable L — X bond is a carbonate bond, a carboxylate ester bond, a phosphate ester bond, an anhydride bond, an acetal bond, a ketal bond, an imine bond, an orthoester bond, a thioester bond a carbamate bond, a urea bond, an amide bond. In a particular sub-embodiment, the L — X bond in a carbonate or carbamate bond. [0048] In certain embodiments, n is from about 1 to about 100, from about 1 to about 75, from about 1 to about 50, from about 1 to about 30 or from about 1 to about 20. In certain embodiments, n is from about 1 to about In various embodiments, n is from about 11 to about 30, from about 13 to about 27, from about 15 to about 25, or from about 17 to about 22. In various other embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, or 25. In a particular embodiment, n is from about 11 to about 14. [0049] In certain embodiments, the biomolecule-polymer conjugate of the disclosure is degradable. This is advantageous in that the biomolecule-polymer conjugate may be initially stable for a period of time when introduced into a living system. This allows time for biomolecule-polymer conjugate to traverse harsh environments, such as the intestinal tract, circulatory system and liver, where the biomolecule alone could be trapped or degraded. The degradable nature of the biomolecule-polymer conjugate allows for the release of the biomolecule to the respective site of action in a living system full intact. The delay of degradation of the biomolecule-polymer conjugate allows for distribution to a variety of tissues and organs that would be less accessible by the biomolecule alone. In addition, the biomolecule-polymer conjugate may also allow for slow release of the biomolecule
dependent on the rate of degradation. In certain embodiments, the biomolecule-polymer conjugate degrades in vivo to release the biomolecule with a half- life of less than about 2 weeks, less then about 1 week, less than about 2 days, less than about 1 day, less than about
12 hours, less than about 6 hours, or less than about 3 hours.
[0050] In certain embodiments, the biomolecule-polymer conjugate of the disclosure has enhanced stability compared to the corresponding unmodified biomolecule, for example in vivo stability as evidenced by, for example, circulation half-life.
[0051] In various embodiments, the biomolecule is released from the protecting polymer layer via degradation of a bond, e.g., the L — X bond, through which the biomolecule is conjugated to the polymer. In various embodiment, the degradation occurs via hydrolysis
(reaction with water) under basic or acid conditions, metabolism, enzymatic degradation (by environmental and/or physiological enzymes), and other biological processes (such as those under physiological conditions in a vertebrate, such as a mammal). In embodiments where the degradation of the biomolecule-polymer conjugate generated acid functional groups (e.g., when the degradation occurs at an ester or carbonate bond), the degradation process provides an auto-catalytic effect.
[0052] In various embodiments, release of the biomolecule may involve the degradation of a biodegradable linker, or digestion of the polymer into smaller, non-polymeric subunits.
Two different areas of biodegradation may occur: the cleavage of bonds in the polymer backbone which generally results in monomers and oligomers of the polymer; or the cleavage of a bond connecting the polymer to the biomolecule. In certain embodiments, the release of the biomolecule (e.g., the degradation of a bond linking the biomolecule to the polymer) occurs faster than the degradation of the biomolecule itself. The degradation rate can be measured both in vitro by known methods, for example by UV- Vis spectroscopy, or in vivo, by sampling blood serum over time and determining the concentration of the metabolits by known methods, for example HPLC.
[0053] The degradation rates of a bond linking the biomolecule to the polymer (such as the L — X bond) and of the polymer itself may vary.
[0054] In certain embodiments, the biomolecule-conjugate of the disclosure is useful for the treatment or prevention or amelioration of a disease, for the modulation of protein/mRNA expression, or as a diagnostic tool.
[0055] In another aspect of the disclosure, provided herein is a composition comprising a biomolecule-polymer conjugate(s) as described herein and a carrier.
Methods of Preparing the Biomolecule-Polymer Conjugate
[0056] In another aspect of the disclosure, a method of preparing the biomolecule- polymer conjugates of Formula 1. The method comprises (a) reacting the biomolecule with an alkyne-containing electrophilic reagent, and (b) reacting the alkyne-modifϊed biomolecule with an azide-containing polymer or mixture of azide-containing polymers. The reaction is illustrated in Scheme 1 below:
Q-L^≡ biomolecule XH)_ biomolecule -X-L- ≡
Scheme 1 where the biomolecule, the polymer, X, L, and n are as defined above, and Q is a leaving group.
[0057] In certain embodiments, steps (a) and (b) are conducted as a "one-pot" synthesis, without isolation and/or purification of the intermediate alkyne-modified biomolecule. In other embodiments, steps (a) and (b) are conducted with isolation and/or purification of the intermediate alkyne-modified biomolecule.
[0058] In step (a) of the method, the biomolecule is reacted with an alkyne-containing electrophilic reagent to yield an L — X bond. In certain embodiments, the alkyne-containing electrophilic reagent is a carboxylic acid, an acid halide, a carboxylic acid anhydride, a carboxylic acid salt, a carboxylic acid ester, an isocyanate, a carbonate, a carbamate, or a chloroformate. In a certain embodiment, the alkyne-containing electrophilic reagent is
wherein q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4. In various sub-embodiments, q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In a particular
sub-embodiment, q is 2. In various sub-embodiments, each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S. In a particular embodiment, the alkyne-containing electrophilic reagent is a chloroformate, such as propargyl chloroformate.
[0059] In various embodiments, step (a) of the method proceeds via one or more of the following reactions (where R is the biomolecule, and X is either OH or NH2): Alcohol + propargyl Chloride, condensation reaction yields an carbonate bond
Alcohol + carboxylic acid, condensation reaction yields an ester bond O O
R-OH + HO^^^. "" * O^^^,
Alcohol + acid halide, condensation reaction yields an ester bond O O
R-OH + Cl^^^^ " * O^^^.
Alcohol + acid anhydride, condensation reaction yields an ester bond
O O °
R-OH + ^^"^O^^^ " Rv°
Alcohol + acid salts, condensation reaction yields an ester bond
Alcohol + ester, transesterification reaction yields an ester bond O O
R,
R-OH + ' ^QT ^ ^. XT ^ ^
Amine + isocyanate, addition reaction yields a urea bond
Amine + acid anhydride, substitution reaction yields an amide bond
Amine + acid halide, substitution reaction yields an amide bond
Amine + acid salts, reaction yields an amide bond
Amine + ester, reaction yields an amide bond
O O
R-NH2 + ^O^^^ " "V^^-
[0060] While the above exemplary reac Rti-ons are illustra.ted where the alkyne 3 atoms away from the biomolecule atom (either the nitrogen or the oxygen), the disclosure encompasses other embodiments where the alkyne is anywhere from 1 to about 20 atoms away from the biomolecule atom. In other embodiments, the alkyne is from about 2 to about 10, or from about 2 to about 5 atoms away from the biomolecule atoms. [0061] Step (a) of the can be conducted in a variety of solvents. In various embodiments, the first step of the method is conducted in water, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, ether, or a mixture thereof. In a particular embodiment, the first step of the method is conducted in a mixture of water and one or more of tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, or
ether. In certain embodiments, the reaction is conducted in the absence of water. In other embodiments, the reaction is conducted in water.
[0062] In certain embodiments, step (a) of the method is conducted in the presence of a base. In various embodiments, the base is a tertiary alkyl amine, an aromatic amine, a carbonate, or a hydroxide. In particular embodiments, the base is diisopropylethylamine, triethylamine, pyridine, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, or potassium hydroxide. [0063] Step (a) of the method can be conducted at a variety of temperatures and times, provided that the biomolecule is not degraded. In certain embodiments, the reaction is conducted at a temperature from about -30 0C to about 25 0C, from about 0 0C to about 25 0C, or from about 5 0C to about 20 0C. In certain embodiments, the reaction is conducted for from about 5 minutes to about 8 hours, from about 5 minutes to about 1 hour, from about 20 minutes to about 40 minutes.
[0064] In certain embodiments, the biomolecule is treated with from about 0.001 to about 1000 molar equivalents of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule. In various embodiments, the biomolecule is treated with from about 0.001 to about 1, from about 0.01 to about 1, from about 0.1 to about 1, or from about 0.5 to about 1 molar equivalent of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule. In other embodiments, the biomolecule is treated with from about 1 to about 1000, from about 1 to about 500, from about 1 to about 100, from about 1 to about 10,or from about 1 to about 5 molar equivalents of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule.
[0065] Optionally, the biomolecule can be treated prior to step (a) of the method. In certain embodiment, the pre-treatment is a desalting, denaturing, or splitting double stranded molecules into single strands.
[0066] In step (b) of the method, the alkyne-modified biomolecule is reacted with one or a mixture of azide-containing polymers. The azide-containing polymer can be any biocompatible polymer with an azide group. In certain embodiments, the azide-containing polymer imparts a stabilizing effect on the biomolecule. When n is greater than 1, the various polymers of Formula 1 can be the same or different. In various embodiments, the azide- containing polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof. In various embodiments,
the azide-containing polymer is a homopolymer, a block copolymer, or a random copolymer. In certain embodiments, the azide-containing polymer is polydisperse or monodisperse. In various embodiments, the polydispersity index of the azide-containing polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the azide-containing polymer is linear. In certain embodiments the azide-containing polymer is branched.
[0067] In certain embodiments, the azide-containing polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefϊn, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cellulosic, a starch, a naturally occurring polymer, a poly(vinyl imidazole), a polyacetal, a polysulfone, a chlorosulphonate polyolefm, or a blend or copolymer thereof. In particular embodiments, the azide-containing polymer is PEG-azide.
[0068] In various embodiments, the azide-containing polymer has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500. In various embodiments, the azide-containing polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000. In a particular embodiment, the azide- containing polymer has an average molecular weight of from about 500 to about 5,000. [0069] In certain embodiments, the azide-containing polymer is independently terminated with a non-functional group, such as a methyl or methoxy, or a functional group, such as a targeting group. In a particular embodiment, the targeting group is a folate. In certain embodiments, the azide-containing polymer is a mixture of non-functional terminated and functional terminated polymers. In certain embodiments, the mixture is a mixture of methoxy terminated and folate-terminated polymers, for example a mixture of methoxy- terminated PEG and folate-terminated PEG. In certain embodiments, the polymer is terminated with another biomolecule. In such an embodiment, the biomolecule -polymer
conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
[0070] Step (b) of the method can be conducted in a variety of solvents. In various embodiments, step (b) of the method is conducted in methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, ether, water, or a mixture thereof. In a particular embodiment, step (b) of the method is conducted in a mixture of water and one or more of methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, or ether. In a particular embodiment, step (b) of the method is conducted in water. [0071] Step (b) of the method can be conducted at a variety of temperatures and times, provided that the biomolecule is not degraded. In certain embodiments, the reaction is conducted at a temperature from about -30 0C to about 70 0C, from about 0 0C to about 65 0C, or from about 25 0C to about 65 0C. In certain embodiments, the reaction is conducted for from about 1 minute to about 8 hours, from about 5 minutes to about 3 hour, or from about 20 minutes to about 60 minutes.
[0072] In certain embodiments, step (b) of the method is conducted in the presence of a catalyst, for example in the presence of a copper catalyst. In a particular sub-embodiment of this embodiment, the copper catalyst is copper bromide or copper iodide. In certain embodiments, step (b) of the method is conducted in presence of a mixture of copper(II), e.g., copper(II) sulfate, and a reducing agent, e.g., sodium ascorbate.
[0073] In certain embodiments, step (b) of the method is conducted in the absence of a catalyst, for example in the absence of a metal catalyst such as copper. In these embodiments, the absence of a catalyst such as a copper catalyst may be particularly advantageous as the produced biomolecule-polymer conjugate is substantially free of copper. In various embodiment, the copper-free method produced a biomolecule-polymer conjugate that contains less than about 100 ppm copper, less than about 10 ppm copper, or less than about 1 ppm copper.
[0074] In certain embodiments, the method further comprises (c) purifying the biomolecule-polymer conjugate. In various embodiments, the conjugate is purified by size exclusion chromatography, reverse phase chromatography, thin layer chromatography, ion exchange chromatography, column chromatography, precipitation, or liquid-liquid extraction. In a particular embodiment, the conjugate is purified size exclusion chromatography.
[0075] In embodiments where the biomolecule is an RNA, modifiable nucleotides (i.e., adenine, guanine, cytosine, and uracil) are denoted in Formula 2. The reactive groups on the RNA include, but are not limited to, primary amines (i.e., where X in Formula 1 is NH), secondary amines (i.e., where X in Formula 1 is NR), and hydroxyl groups (i.e., where X in Formula 1 is O). In certain embodiments, only the primary amines and hydroxyl groups are modifiable. Secondary amines on natural RNAs are generally less reactive than primary amines, and thus may not always be modified in accordance with the method of the disclosure.
Adenine Guanine Cytosine Uracil
Formula 2. RNA nucleotides
[0076] Specifically, the reactive moieties on the RNA nucleotides can be reacted with propargyl chloroformate. This reaction may be undertaken in a variety of different solvents or solvent mixtures. This reaction may also be undertaken in the presence or absence of bases, acids, acid scavengers, water scavenger, or drying reagents. [0077] In embodiments where the biomolecule is an RNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, Formula 3 illustrate the modification of all reactive groups in each of the nucleotides. In other embodiments, the nucleotides are incompletely modified. It will be understood that each of the illustrated nucleotides is part of an oligonucleotide or polynucleotide chain, and thus the number of alkyne groups on a given RNA oligonucleotide or polynucleotide can vary. In various embodiments, the RNA comprises from about 1 to about 50, from about 5 to about 40, from about 10 to about 35, from about 10 to about 20, from about 20 to about 35, from about 10 to about 15, from about 15 to about 20, from about 20 to about 25, from about 25 to about 30, and from about 30 to about 35 alkyne groups after step (a) of the method.
Formula 3. Alkyne-Modifϊed RNA Nucleotides
[0078] In embodiments where the biomolecule is an RNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, Formula 4 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and the alkyne appended to an adenine. The alkyne group reacts with an azide end group of a polymer chain to form a triazole linkage. As seen in Formula 4, the resulting biomolecule-polymer conjugate exhibits a regioisomerism, that is there are two regioisomers formed at the triazole. This regioisomerism is illustrated by the loose bond in Formula 1.
Formula 4. RNA nucleotide-polymer conjugate at one position
[0079] In embodiments where the biomolecule is an RNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, Formula 5 illustrates the product
of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and two alkyne groups appended to an adenine. Each of the alkyne groups reacts with an azide end group of a polymer chain to form more than one triazole linkage As seen in Formula 5, the resulting biomolecule- polymer conjugate exhibits a regioisomerism, that is there are two regioisomers formed at each triazole. Thus, in an embodiment where there are two alkyne groups on one nucleobase, four regioisomers may be formed.
Formula 5. RNA nucleotide-polymer conjugate at two positions
[0080] In embodiments where the biomolecule is an RNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, Formula 6 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and one or two alkyne groups
appended to guanine, cytosine, and uracil. As is also noted above, the modification of these nucleotides can embody single or multiple linkers to one or more polymer chains by forming one or more triazole rings as is illustrated in Formula 6.
Formula 6. RNA nucleotide-polymer conjugates
[0081] In embodiments where the biomolecule is an RNA and the alkyne-containing electrophilic reagent is propargyl chloro formate, the modification of the RNA may occur at the sugar hydroxyl only, as illustrated in Formula 7. Without intending to be limited by mechanism, it is believed that this mode of modification occurs for double-stranded oligonucleotides, where the base pairing precludes modification of the base itself.
Formula 7. Alkyne-modified RNA nucleotides (sugar hydroxyl only)
[0082] In embodiments where the biomolecule is an RNA, the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, and only the sugar hydroxyl has been alkyne-modifϊed, Formula 8 illustrates the product of the cycloaddition reaction between an azide-containing polymer (e.g., PEG azide terminated with a methoxy group or a targeting group) and the alkyne group appended to adenine, guanine, cytosine, and uracil.
Formula 8. RNA nucleotide-polymer conjugates (sugar hydroxyl only)
[0083] In other embodiments, the above-described method is analogously applied to DNAs. Natural DNA incorporated thymine, which, in embodiments where the biomolecule is a DNA and the alkyne-containing electrophilic reagent is propargyl chloroformate or the like, can be modified to form the product illustrated in Formula 9.
Formula 9. Thymine and DNA thymine-polymer conjugate.
[0084] It will be understood that the methods may be analogously applied to biomolecules besides DNAs and RNAs, as described above. Kits
[0085] In another aspect of the disclosure, a kit suitable for preparing the biomolecule- polymer conjugate of the disclosure is provided, the kit comprising an alkyne-containing electrophilic reagent in a first container, an azide-containing biocompatible polymer in a second container, and instructions for their use.
[0086] In certain embodiments, the alkyne-containing electrophilic reagent is a carboxylic acid, an acid halide, a carboxylic acid anhydride, a carboxylic acid salt, a carboxylic acid ester, an isocyanate, a carbonate, a carbamate, or a chloro formate. In a particular embodiment, the alkyne-containing electrophilic reagent is
where q is an integer from 0 to about 20, from about 0 to about 10, from about 1 to about 10, from about 2 to about 10, from about 2 to about 8, from about 2 to about 5, or from about 2 to about 4. In various sub-embodiments, q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In a particular sub-embodiment, q is 2. In various sub-embodiments, each methylene group may be optionally substituted, or may itself be a different atom, such as NH, O, or S. In a particular
embodiment, the alkyne-containing electrophilic reagent is a chloroformate, such as propargyl chloroformate
[0087] The azide-containing polymer can be any biocompatible polymer with an azide group. In certain embodiments, the azide-containing polymer imparts a stabilizing effect on the biomolecule. When n is greater than 1, the various polymers of Formula 1 can be the same or different. In various embodiments, the azide-containing polymer is independently anionically charged, cationically charged, or uncharged; hydrophobic, hydrophilic, or amphiphilic; or combinations thereof. In various embodiments, the azide-containing polymer is a homopolymer, a block copolymer, or a random copolymer. In certain embodiments, the azide-containing polymer is polydisperse or monodisperse. In various embodiments, the polydispersity index of the azide-containing polymer is from 1 to about 30, from 1 to about 10, from 1 to about 5, or from 1 to about 3. In certain embodiments the azide-containing polymer is linear. In certain embodiments the azide-containing polymer is branched. [0088] In certain embodiments, the azide-containing polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene-vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefm, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cellulosic, a starch, a naturally occurring polymer, a poly(vinyl imidazole), a polyacetal, a polysulfone, a chlorosulphonate polyolefm, or a blend or copolymer thereof. In particular embodiments, the azide-containing polymer is PEG-azide.
[0089] In various embodiments, the azide-containing polymer has an average molecular weight of from about 200 to about 50,000, from about 200 to about 40,000, from about 200 to 30,000, from about 200 to about 20,000, from about 200 to about 10,000, from about 200 to about 5,000, from about 200 to about 4,000, from about 200 to about 3,000, from about 200 to about 2,000, from about 200 to about 1,000, or from about 200 to about 500. In various embodiments, the azide-containing polymer has an average molecular weight of from about 10,000 to about 50,000, from about 10,000 to about 40,000, from about 10,000 to about 30,000, or from about 10,000 to about 20,000. In a particular embodiment, the azide- containing polymer has an average molecular weight of from about 500 to about 5,000.
[0090] In certain embodiments, the azide-containing polymer is independently terminated with a non-functional group, such as a methyl or methoxy, or a functional group, such as a targeting group. In a particular embodiment, the targeting group is a folate. In certain embodiments, the azide-containing polymer is a mixture of non-functional terminated and functional terminated polymers. In certain embodiments, the mixture is a mixture of methoxy terminated and folate-terminated polymers, for example a mixture of methoxy- terminated PEG and folate-terminated PEG. In certain embodiments, the polymer is terminated with another biomolecule. In such an embodiment, the biomolecule -polymer conjugate is a networked biomolecule-polymer conjugate, each conjugate comprising more than one biomolecule.
[0091] In certain embodiments, the first container further comprises a first solvent. In certain embodiments, the first solvent is water, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, ether, or a mixture thereof. In certain embodiments, the first solvent is a mixture of water and one or more of tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, pyridine, acetone, or ether. In a particular embodiment, the first container does not comprise water. In a particular embodiment, the first solvent is water. [0092] In certain embodiments, the second container further comprises a second solvent. In various embodiments, the second solvent is methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, ether, water, or a mixture thereof. In a particular embodiment, the second solvent is water and one or more of methanol, ethanol, propanol, isopropanol, tetraethylene glycol dimethylether, dimethylsulfoxide, dimethylformamide, acetone, or ether. In a particular embodiment, the second solvent is water.
[0093] The kit optionally further comprises one or more containers comprising the following: a base, a metal catalyst, a solvent, a purification column, a filter, a drying agent, a mixing vessel, a magnetic stirbar, and a filtration vessel.
[0094] In a particular embodiment, the kit comprises instructions to (1) dissolve the biomolecule in a first solvent (optionally provided with the kit); (2) add the alkyne-containing electrophilic reagent to the solution of the biomolecule; (3) optionally add a base to the solution of the biomolecule and alkyne-containing electrophilic reagent; (4) stir for between 30 minutes and 8 hours, or for between 1 hour and 2 hours; (5) remove solvent, alkyne- containing electrophilic reagent, and optional base; (6) dissolve the alkyne-modified
biomolecule in a second solvent (optionally provided with the kit); (7) add the azide- containing polymer; (8) optionally add the metal catalyst; (8) stir for between 1 and 24 hours, or for about 2 hours, at room temperature or at a temperature from 35 0C to about 80 0C; (9) optionally concentrate the reaction mixture; (10) optionally purify using filter or column (optionally provided with the kit). The final product of the kit may be used in a cell based assay or as a diagnostic tool for laboratory use. [0095] The disclosure will be further understood by the following non-limiting examples.
Example 1 : Alkyne-Modification of an Oligonucleotide
[0096] A model oligonucleotide, 5 ' -TTTT ATTTTATTTT ATTTT A-3 ' (SEQ ID NO: 1), can be modified according to the method of the disclosure. The model oligonucleotide (1 mg) is dissolved in 20μL of dimethyl formamide (DMF) at room temperature. To this mixture is added propargyl chloro formate (1.8 μL), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N2 and the residue analyzed by
Nuclear Magnetic Resonance (NMR) spectroscopy. While FIG. IA only shows alkyne modification at one site, it is understood that such modification may occur at every modifiable site on the biological molecule. Therefore, in the model oligonucleotide, alkyne modification may occur at every adenine site.
[0097] FIG. IB shows an oligonucleotide segment in which each nucleic acid base is alkyne-modified.
Example 2: Conjugation of Alkyne-Modified Biomolecule to PEG Azides
[0098] Click chemistry was first coined by Smalley et al. in 2001. The method of the disclosure makes use of the click chemistry Azide- Alkyne Huisgen Cycloaddition reaction.
This "click reaction," cleanly and efficiently attached an azide functional polymer to an alkyne-modified biomolecule. FIG. 2 illustrates an embodiment of the method using methoxy-terminated PEG-azide and a biomolecule modified with propargyl chloroformate or the like.
[0099] The method of the disclosure can be conducted as a "one -pot" reactions without isolation or cleaning of the products from the alkyne modification reaction. A representative reaction is as follows: the alkyne-modified biomolecule is dissolved in 30μL of DMF. PEG azide is added to this mixture and the reaction mixture is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N2 and analyzed by NMR spectroscopy.
[0100] FIG. 3 A illustrates an embodiment of the method. Using click chemistry, the biomolecule, in this case siRNA, is alkyne -modified at several locations along the nucleotide sequence. Several azide functional PEG chains are attached to the modified siRNA at the alkyne modification sites via the click reaction, creating an siRNA-polymer conjugate comprising multiple PEG strands.
Example 3: Conjugation of Alkyne-Modified Proteins to PEG Azides
[0101] Hemoglobin (1 mg) is dissolved in 30 μL of DMF at room temperature. To this mixture is added propargyl chloro formate (1.8 μL), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N2 and the residue analyzed by
NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, for example at a cysteine SH (e.g., Cys34). The alkyne- modified hemoglobin is then dissolved in 30μL of DMF. PEG azide (10 μL) is added to this mixture and the reaction is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N2 and analyzed by NMR spectroscopy.
[0102] FIG. 3B illustrates an embodiment of the method. Using click chemistry, the biomolecule, in this case hemoglobin, is modified at several locations. Azide-containing molecules (e.g., homopolymers, copolymers, or other small molecules) are attached to the modified biomolecule at the modification sites via the click reaction, creating a biomolecule conjugate comprising multiple conjugates homopolymers, copolymers, or other small molecules.
[0103] Hemoglobin is useful as a blood substitute, and thus the hemoglobin-polymer conjugates of the disclosure may be useful as prodrugs of hemoglobin. See, e.g., P. W.
Buehler et al, Biomaterials, 2010, 31, 3723-3735.
Example 4: Conjugation of Alkvne -Modified Peptides to PEG Azides
[0104] The peptide PYY (0.25 mg) is dissolved in 25μL of DMF at room temperature.
To this mixture is added propargyl chloroformate (1.8 μL), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N2 and the residue analyzed by NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, for example at a tyrosine phenolic OH. The alkyne-modifϊed peptide is then dissolved in 25 μL of DMF. PEG azide (1 μL) is added to this mixture and the reaction mixture is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N2 and analyzed by NMR spectroscopy. FIG. 3B is also representative of this reaction.
[0105] PYY has been implicated in the treatment of obesity, and thus PYY-polymer conjugates of the disclosure may be useful prodrugs of PYY. See Marianne T. Neary et al.,
Pharmacology & Therapeutics, 2009, 124(1), 44-56.
Example 5: Conjugation of Alkyne-Modified Polysaccharide PEG Azides
[0106] The polysaccharide chitosan (1 mg) is dissolved in 20μL of DMF at room temperature. To this mixture is added propargyl chloroformate (2 μL), and the reaction mixture is allowed to stir for 2 hours. The reaction mixture is then concentrated under N2 and the residue analyzed by NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, such as a glucosamine NH2 or
CH2OH. The alkyne-modfied chitosan from the modification reaction is dissolved in 30 μL of DMF. PEG azide (2 μL) is added to this mixture and the reaction mixture is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N2 and analyzed by NMR spectroscopy. FIG. 3B is also representative of this reaction.
[0107] Chitosan may be useful for the treatment of various diseases, for example those characterized by over-expression of folic acid receptor cells, and thus chitosan-polymer conjugates of the disclosure may be useful as prodrugs of chitosan. See, e.g., U.S. Patent
Application Publication No. 2009/324726 ("Fernandes et al.").
Example 6: Conjugation of Alkyne-Modified Nucleotide to PEG Azides
[0108] The nucleotide adenosine triphosphate (ATP) (lmg) is dissolved in 30 μL of DMF at room temperature. To this mixture is added propargyl chloroformate (1 μL), and the reaction is allowed to stir for 2 hours. The reaction mixture is then concentrated under N2 and the residue analyzed by NMR spectroscopy. It is understood that such modification may occur at every modifiable site on the biological molecule, for example a sugar OH or the adenine NH2. The alkyne-modified nucleotide from the modification reaction is dissolved in
30 μL of DMF. PEG azide (6 μL) is added to this mixture and the reaction is allowed to stir for 2 hours at room temperature. The reaction mixture is concentrated under N2 and analyzed by NMR spectroscopy. FIG. 3B is also representative of this reaction.
Example 7: Alkyne-Modification of Oligonucleotide and Conjugation to Azide-Containing
Polymer
[0109] An RNA or DNA oligonucleotide (0.1 mg) is dissolved in 20 μl of tetraethylene glycol dimethylether at room temperature. This is followed by the addition of 5 to 20 μl of diisopropylethylamine at room temperature. Propargyl chloroformate (0.5 μl) is then added, and the reaction mixture is allowed to stir for approximately 30 minutes. All volatile
components are removed. Methanol (20 μl) is added. The azide-containing polymer (1 to 3 μl or 1 to 3 mg) is added and the reaction mixture stirred for approximately 1 hour. All volatiles are removed. The resulting product is then analyzed by HPLC. Example 8: Preparation of Azide-Containing Polymer Terminated with a Targeting Group [0110] The carboxylic acid of folate (300mg) is first activated by reacting with N- hydroxysuccimide (NHS) and N^'-Dicyclohexylcarbodiimide (DCC) in dimethyl sulfoxide (DMSO) stirred for 18 hours, filtered and washed with 30% acetone-ether to give the corresponding activated ester. This activated ester is then dissolved in dry pyridine and stirred with monoamine PEG azide for 18 hours. The pyridine is evaporated and the resulting mixture chromatographed to give the folate functionalized PEG azide. This folate functionalized PEG azide can be attached to a biomolecule as previously mentioned. [0111] FIG. 3 C illustrates an embodiment of the disclosure where the alkyne-modified biomolecule (e.g., siRNA) is conjugated to an azide-containing polymer terminated with a functional group such as a targeting group. The azide-containing polymers terminated with a functional group are conjugated to the alkyne-modified sites on the biomolecule via the click reaction, creating a biomolecule-polymer conjugate comprising multiple polymer strands terminated with a functional group.
Example 9: Conjugation of Alkyne -Modified Oligonucleotide to PEG Azides to Form Networks
[0112] As illustrated FIG. 4, in one embodiment, polymer chains (e.g., PEG) of varying lengths are bonded to a copolymer having multiple azide functional sites (A). In another embodiment, the copolymer includes cationic groups along the backbone (B). In another embodiment, the polymer chains (e.g., PEG) of varying lengths can also be bonded to a multifunctional azide homopolymer segment (C). An alkyne-modified biomolecule is then conjugated to the polymer having multiple azide groups (A, B, or C), via the click reaction, to form a network of biomolecules and polymers (D). The additional azide functionalities on the polymers allows each polymer to form bonds with multiple biomolecules creating a network of bonded biomolecules and polymers.
[0113] It was originally suspected that such network formations would provide improved protection for the oligonucleotides. Work with the PCR primers showed that the networks show extended protection times of the functional oligonucleotide. Protection of biological molecules with multiple monofunctional azides and no additional networking is the preferred method and was studied most extensively in protection studies because this research has
shown that it provides adequate protection and has the advantages of 1) simple polymer reactants; 2) simple separation of unreacted monomer (via dialysis); and 3) the reaction is less prone to leaving unreacted alkyne groups on the modified oligonucleotides. However, the networks have been shown to provide longer term protection of the oligonucleotides and can be used if they are found to be superior in specific cases (or may have potential as extended release systems).
Example 10: Study of Stability and Resistance to Degradation of an Oligonucleotide- Polvmer Conjugate
[0114] Nucleases and proteases are common and result in extremely short half-life for biomolecules not protected from the in vivo environment. In addition, carboxylesterases (CES) are known to be present in many cancerous tumor cells. Therefore, the ability of the biomolecule-polymer conjugates of the disclosure to withstand degradation in the presence of fetal calf serum (FCS) and either DNase I, or Sl nuclease is investigated, as well as the ability of carboxylesterase 1 to degrade the biomolecule-polymer conjugates and release the biomolecule.
[0115] Concentrations of treatments were as follows: FCS (30%), DNase I (30 units), Sl nuclease (10 units). Digestions were conducted at 370C and monitored by either thin layer chromatography or gel electrophoresis. FIG. 5 shows TLC results under UV light showing DNase I digestion after one hour of the model oligonucleotide of Example 1 conjugated to MPEG550 (methoxy-terminated PEG, MW 550), the model oligonucleotide alone, and a blend of the model oligonucleotide and MPEG550. As shown in FIG. 5, it was found that the oligonucleotide-MPEG conjugate was resistant to DNase I treatment compared to the native model oligonucleotide and the blend of native model oligonucleotide and MPEG550. [0116] FIG. 6 shows TLC results under UV light showing DNase I digestion after six hours of the model oligonucleotide and the oligonucleotide-MPEG conjugate. As can be seen in Figure 6, the native model oligonucleotide was completely digested after 6 hours while the oligonucleotide-MPEG conjugate remained intact.
[0117] In addition, the chemical degradation of the oligonucleotide-MPEG conjugate using ammonium hydroxide (NH4OH) (to cleave the L — X bond) allowed for degradation by DNase I after 3 hours, as shown in FIG. 7. This demonstrates that the conjugation of the biomolecule protects the biomolecule from digestion, but that the conjugation is reversible. Example 11 : Functional Sequence Results K-ras
[0118] The functional K-ras was modified according to the method of Example 7 using MPEGβk (methoxy-terminate PEG, MW 6000) at low (one equivalent MPEGβk, i.e., n is about 1), medium (six equivalents MPEGβk, i.e., n is about 6), and high substitution (excess MPEGβk, i.e., n is about 11 - 30), and evaluated for stability in the presence of DNase I. FIG. 8 shows TLC results under UV light (left) and vanillin stained (right) showing DNase I digestion after 48 hours of K-ras, a blend of K-ras and MPEGβk, Rras conjugated to one equivalent MPEGβk, i.e., n is about 1, K-ras conjugated to about six equivalents MPEGβk, i.e., n is about 6, and K-ras conjugated to excess MPEGβk, i.e., n is about 11 - 30. As shown in FIG. 8, even a small amount of substitution aids in the prevention of degradation in DNase I over the control. In addition, a high amount of substitution gives significant protection against degradation. This may allow for a selective level of modification in order to tailor the circulation time desired for a given therapy. Example 12: Functional Sequence Results PCR Primer
[0119] The retention and recovery of the original functionality of the biomolecule is a characteristic of the conjugates of the disclosure. In order to test the ability of an oligonucleotide-polymer conjugate of the disclosure to functionally bind its complementary sequence, PCR primers were utilized. The universal bacterial primers 8F (5'- AGAGTTTGATCCTGGCTCAG-3', SEQ ID NO:2) and 1392R (5'-
ACGGGCGGTGTGTACA-3', SEQ ID NO:3) were used to amplify a portion of the bacterial 16S ribosomal RNA gene. The 8F primer conjugated to MPEG-550 networked with MPEG- 550 were prepared according to Examples 7 and 9 above, and subjected to DNase I degradation studies. FIG. 9 shows TLC results under UV light (left) and vanillin stained (middle) showing DNase I digestion after one hour of PCR primer (control), PCR primer (digest), the MPEG550 conjugate, and the MPEG550-networked-conjugate. [0120] As shown in FIG. 9, the MPEG550 conjugate and the MPEG550-networked- conjugate were resistant to nuclease degradation. The MPEG550 conjugate and the MPEG550-networked-conjugate were then treated with NH4OH to release the PCR primers from the MPEG550 via chemical degradation and PCR amplification was then performed. Each 50-μl PCR mixture contained 1 μl template DNA (either E. coli. or an environmental isolate belonging to the genus Streptomonospora), 2 U Taq DNA polymerase (Eppendorf ), Ix Taq buffer, 2.75 μM Mg(OAc)2, Ix Taq Master PCR Enhancer, each deoxynucleoside triphosphate at a concentration of 20 μM , and each primer at a concentration of 0.4 μM. The PCR conditions were 85°C for 5 min, 30 cycles of 94°C for 45 s, 55°C for 1 min, and 72°C
for 90 s, with a final 7 min extension at 72°C. The right side of FIG. 8 shows gel electrophoresis results in a 1% agarose gel showing the PCR amplification products of PCR primer (unmodified 8F primer), MPEG550 conjugate, and the MPEG550 conjugate cleaved in NH4OH for 15 minutes and 18 hours. It was found that the MPEG550 conjugates were functional and yielded the appropriate size amplification product, as did the NH4OH treated MPEG550 conjugate, however no amplification product was detected for the MPEG550- networked-conjugate. Nevertheless, FIG. 9 also shows that the MPEG550 conjugate and MPEG550-networked-conjugate show excellent protection when exposed to DNase I over the unmodified PCR primer.
Example 13: Functional Sequence Results Salmon Sperm DNA: [0121] Salmon sperm (SS) DNA was used as an example biomolecule. An SS- MPEG550 conjugate was prepared according to Example 7 and digested with Sl Nuclease. FIG. 10 shows TLC results under UV light (left) and vanillin stained (right) showing Sl Nuclease digestion after 30 minutes of SS DNA (control) and SS-MPEG550 conjugate. As can be seen in FIG. 10, when exposed to the very aggressive Sl Nuclease, the SS-MPEG550 conjugate is stable while the native SS DNA is almost completely digested. Example 14: Functional Sequence Results siRNA
[0122] Functional p53 siRNA was conjugated to MPEG 550 according to the method of Example 7 and evaluated for stability against FCS. FIG. 11 shows TLC results under UV light showing FCS digestion after 36 hours with samples including siRNA (control), siRNA- MPEG550 conjugate (control), siRNA (digest), and siRNA-MPEG550 conjugate (digest). As can be seen in FIG. 11, when the siRNA-MPEG550 conjugate is exposed to 30% FCS for 36 hours, conditions in which the siRNA alone is completely degraded, the siRNA-MPEG550 conjugate remains stable.
[0123] The examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments, and are not intended to limit the scope of what is disclosed herein. Modifications that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference..
Claims
1. A biomolecule-polymer conjugate of Formula 1 :
Formula 1 wherein
X is independently O, NH, NR, or S, and X and R are independently atoms of the biomolecule;
L is independently a 1 - 20 atom linear or branched linker; n is an integer; the polymer is a biocompatible polymer; and wherein the X — L bond is degradable.
2. The conjugate of claim 1 , wherein the biomolecule is a peptide, polypeptide, protein, polysaccharide, nucleic acid, nucleotide, amino acid, polynucleotide, or a mixed group thereof.
3. The conjugate of claim 1 or 2, wherein the biomolecule is a DNA or RNA.
4. The conjugate of claim 3, wherein the DNA or RNA comprises about 2 to about 30 bases.
5. The conjugate of any one of claims 1-4, wherein the biomolecule is an antisense molecule.
6. The conjugate of any one of claims 1-5, wherein the biomolecule is an siRNA or miRNA.
7. The conjugate of any of any one of claims 1 -6, wherein the X — L bond is a carbonate or carbamate bond.
8. The conjugate of any one of claims 1-7, wherein X — L is
9. The conjugate of any one of claims 1-8, wherein the biocompatible polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide- co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene -vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefm, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cellulosic, a starch, a naturally occurring polymer, a poly( vinyl imidazole), a polyacetal, a polysulfone, a chlorosulphonate polyolefm, or a blend or copolymer thereof.
10. The conjugate of any one of claims 1 -9, wherein the biocompatible polymer is methoxy-terminated polyethylene glycol or folate-terminated polyethylene glycol.
11. The conjugate of any one of claims 1-10, wherein the methoxy-terminated polyethylene glycol or folate-terminated polyethylene glycol has an average molecule weight of from about 500 to about 2000.
12. The conjugate of any one of claims 1-11, wherein n is from about 1 to about 30.
13. The conjugate of any one of claims 1-12, wherein n is from about 11 to about 13.
14. The conjugate of any one of claims 1-13, wherein the conjugate is substantially free of copper.
Formula 1 wherein
X is independently O, NH, NR, or S, and X and R are independently atoms of the biomolecule;
L is independently a 1 - 20 atom linear or branched linker; n is an integer; the polymer is a biocompatible polymer; and wherein the X — L bond is degradable; the method comprising a. reacting the biomolecule with an alkyne-containing electrophilic reagent to form a modified biomolecule of Formula B:
biomolecule 4-X-L — =
Formula B wherein the biomolecule, X, L, and n are as defined above; and b. reacting the modified biomolecule of Formula B with a polymer or mixture of polymers of Formula C:
Formula C wherein the polymer is as defined above.
16. The method of claim 15, wherein the biomolecule is a peptide, polypeptide, protein, polysaccharide, nucleic acid, nucleotide, amino acid, polynucleotide, or a mixed group thereof.
18. The method of any one of claims 15-17, wherein the biomolecule is treated with from about 1 to about 1000 molar equivalents of alkyne-containing electrophilic reagent based on the number of modifiable positions on the biomolecule.
19. The method of any one of claims 15-18, wherein the biocompatible polymer is a polyethylene glycol (PEG), a polyether, a poly(lactide), a poly(glycolide), a poly(lactide- co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), a polyanhydride, a polyorthoester, a polycarbonate, a polyetherester, a polycaprolactone, a polyesteramide, a polyester, a polyacrylate, a polymer of ethylene -vinyl acetate or another acyl substituted cellulose acetate, a polyurethane, a polyamide, a polystyrene, a silicone based polymer, a polyolefm, a polyvinyl chloride, a polyvinyl fluoride, a fluoropolymer, a polypropylene, a polyethylene, a cellulosic, a starch, a naturally occurring polymer, a poly( vinyl imidazole), a polyacetal, a polysulfone, a chlorosulphonate polyolefm, or a blend or copolymer thereof.
20. The method of any one of claims 15-20, wherein the polymer or mixture of polymers of Formula C is methoxy-terminated PEG-azide.
21. The method of any one of claims 15-21, wherein the polymer has an average molecular weight of from about 500 to about 2000.
22. The method of any one of claims 15-22, wherein the polymer or mixture of polymers of Formula C is a mixture of methoxy-terminated PEG-azide and folate-terminated PEG-azide.
23. A kit for preparing the biomolecule-polymer conjugate of any one of claims 1 - 14, comprising an alkyne-containing electrophilic reagent in a first container, a polymer or mixture of polymers of Formula C:
Formula C in a second container, and instructions for use.
24. The kit according to claim 23, wherein the alkyne-containing electrophilic reagent is:
25. The kit according claim 23 or 24, wherein the polymer or mixture of polymers of Formula C is methoxy-terminated PEG-azide.
26. The kit according to any one of claims 23-25, wherein the polymer or mixture of polymers of Formula C is a mixture of methoxy-terminated PEG-azide and folate- terminated PEG-azide.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10783955A EP2437789A1 (en) | 2009-06-01 | 2010-06-01 | Biomolecule-polymer conjugates and methods of making same |
US13/375,302 US20120130045A1 (en) | 2009-06-01 | 2010-06-01 | Biomolecule-polymer conjugates and methods of making same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18283809P | 2009-06-01 | 2009-06-01 | |
US61/182,838 | 2009-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010141507A1 true WO2010141507A1 (en) | 2010-12-09 |
Family
ID=43298094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/036957 WO2010141507A1 (en) | 2009-06-01 | 2010-06-01 | Biomolecule-polymer conjugates and methods of making same |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120130045A1 (en) |
EP (1) | EP2437789A1 (en) |
WO (1) | WO2010141507A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103980552A (en) * | 2014-04-30 | 2014-08-13 | 中国科学院化学研究所 | Click chemistry modified chitosan material suitable for 3D printing and preparation method thereof |
WO2014134689A1 (en) * | 2013-03-08 | 2014-09-12 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
CN104761726A (en) * | 2015-01-08 | 2015-07-08 | 湖南工业大学 | Method for adjusting and controlling ordered pore diameters of ethylcellulose-grafted polystyrene polymer material based on main chain length |
US10113033B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
US11207417B2 (en) | 2017-03-14 | 2021-12-28 | Polyactiva Pty Ltd | Drug-polymer conjugate |
US11696955B2 (en) | 2017-03-14 | 2023-07-11 | Polyactiva Pty Ltd | Drug-polymer conjugate |
US11787906B2 (en) | 2017-03-14 | 2023-10-17 | Polyactiva Pty Ltd | Biodegradable drug-polymer conjugate |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160305A1 (en) * | 2013-03-14 | 2014-10-02 | Albany Molecular Research, Inc. | Ligand-therapeutic agent conjugates and silicon-based linkers |
CN113304274A (en) * | 2021-04-23 | 2021-08-27 | 南开大学 | Conjugate, preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032081A1 (en) * | 2002-12-13 | 2005-02-10 | Jingyue Ju | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
US20060189529A1 (en) * | 2004-12-22 | 2006-08-24 | Ambrx, Inc. | Modified human growth hormone |
US20080050731A1 (en) * | 2006-02-10 | 2008-02-28 | Invitrogen Corporation | Labeling and detection of nucleic acids |
US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
-
2010
- 2010-06-01 US US13/375,302 patent/US20120130045A1/en not_active Abandoned
- 2010-06-01 WO PCT/US2010/036957 patent/WO2010141507A1/en active Application Filing
- 2010-06-01 EP EP10783955A patent/EP2437789A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050032081A1 (en) * | 2002-12-13 | 2005-02-10 | Jingyue Ju | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
US20060189529A1 (en) * | 2004-12-22 | 2006-08-24 | Ambrx, Inc. | Modified human growth hormone |
US20080050731A1 (en) * | 2006-02-10 | 2008-02-28 | Invitrogen Corporation | Labeling and detection of nucleic acids |
US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014134689A1 (en) * | 2013-03-08 | 2014-09-12 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
CN105358146A (en) * | 2013-03-08 | 2016-02-24 | 波利艾克蒂瓦有限公司 | Polymer conjugate for delivery of a bioactive agent |
US9572892B2 (en) | 2013-03-08 | 2017-02-21 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
US10111886B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
US10113033B2 (en) | 2013-03-08 | 2018-10-30 | Polyactiva Pty Ltd | Polymer conjugate for delivery of a bioactive agent |
CN103980552A (en) * | 2014-04-30 | 2014-08-13 | 中国科学院化学研究所 | Click chemistry modified chitosan material suitable for 3D printing and preparation method thereof |
CN103980552B (en) * | 2014-04-30 | 2016-02-24 | 中国科学院化学研究所 | Click chemistry modified chitosan material that a kind of applicable 3D prints and preparation method thereof |
CN104761726A (en) * | 2015-01-08 | 2015-07-08 | 湖南工业大学 | Method for adjusting and controlling ordered pore diameters of ethylcellulose-grafted polystyrene polymer material based on main chain length |
CN104761726B (en) * | 2015-01-08 | 2020-05-22 | 湖南工业大学 | Method for regulating and controlling ordered pore diameter of ethyl cellulose grafted polystyrene copolymer material based on main chain length |
US11207417B2 (en) | 2017-03-14 | 2021-12-28 | Polyactiva Pty Ltd | Drug-polymer conjugate |
US11696955B2 (en) | 2017-03-14 | 2023-07-11 | Polyactiva Pty Ltd | Drug-polymer conjugate |
US11787906B2 (en) | 2017-03-14 | 2023-10-17 | Polyactiva Pty Ltd | Biodegradable drug-polymer conjugate |
Also Published As
Publication number | Publication date |
---|---|
US20120130045A1 (en) | 2012-05-24 |
EP2437789A1 (en) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010141507A1 (en) | Biomolecule-polymer conjugates and methods of making same | |
AU2022283737B2 (en) | Defined multi-conjugate oligonucleotides | |
CN106459955B (en) | Antisense nucleic acid | |
EP4372091A2 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
EP3992291A1 (en) | Novel compound and application thereof | |
US20220290145A1 (en) | Modified RNA Agents with Reduced Off-Target Effect | |
CN101534643A (en) | Hindered ester-based biodegradable linkers for oligonucleotide delivery | |
CN110248665A (en) | The polymer oligonucleotides removed with reduced kidney | |
WO2012075117A2 (en) | Small molecule-polymer conjugates and methods of making same | |
CN117858948A (en) | Novel therapeutic agent delivery moieties and uses thereof | |
Drzewińska et al. | Poly (propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity | |
Watts | The medicinal chemistry of antisense oligonucleotides | |
JP2011511776A (en) | Cationic siRNA for RNA interference, synthesis and use | |
JP7231147B2 (en) | RNA introduction reagent and its use | |
WO2022219409A2 (en) | Compositions containing nucleic acid nanoparticles and processes related to alteration of their physicochemical characteristics | |
Menzi | Properties of polyamine-conjugated oligonucleotides | |
Debacker | Improving gene silencing oligonucleotides by incorporation of peptide nucleic acids | |
CN118638166A (en) | GalNAc compound containing triazole structure and oligonucleotide conjugate thereof | |
WO2020025527A1 (en) | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage | |
Noronha | Synthesis Physicochemical and Biological Studies on Oligonucleotides Containing D-arabinose | |
Kiviniemi | Studies on Intrachain Conjugation, Hybridization and Invasion of Oligonucleotides | |
Alagia | Modulation of the RNAi pathway by chemically modified siRNA molecules | |
Jorge et al. | 8 Oligonucleotide conjugates and DNA nanotechnology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10783955 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010783955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13375302 Country of ref document: US |